U.S. patent application number 10/311666 was filed with the patent office on 2003-05-29 for curing method for pathologic syndrome and medicinal preparation.
Invention is credited to Epshtein, Oleg Iliich, Kolyadko, Tamara Mikhailovna, Shtark, Mark Borisovich.
Application Number | 20030099636 10/311666 |
Document ID | / |
Family ID | 20236296 |
Filed Date | 2003-05-29 |
United States Patent
Application |
20030099636 |
Kind Code |
A1 |
Epshtein, Oleg Iliich ; et
al. |
May 29, 2003 |
Curing method for pathologic syndrome and medicinal preparation
Abstract
A method of treating a pathological syndrome includes
administration of an activated form of ultra-low doses of
antibodies to an antigen, wherein said activated form is obtained
by repeated consecutive dilution combined with external impact, and
the antigen is a substance or a pharmaceutical agent exerting
influence upon the mechanisms of formation of this particular
pathological syndrome. Pharmaceutical agent for treating a
pathological syndrome contains activated form of ultra-low doses of
monoclonal, polyclonal or natural antibodies to an antigen, wherein
said activated form is prepared by means of repeated consecutive
dilution and external treatment, predominantly based on homeopathic
technology, and said antigen is a substance or a drug acting as a
direct cause of the pathological syndrome or involved in regulation
of mechanisms of its formation. At that, activated forms of
ultra-low doses of antibodies are raised against antigens of
exogenous or endogenous origin, against autologous antigens, fetal
antigens; anti-idiotypic antibodies are used too.
Inventors: |
Epshtein, Oleg Iliich;
(Kazeny, RU) ; Shtark, Mark Borisovich;
(Zolotodolinskaya, RU) ; Kolyadko, Tamara
Mikhailovna; (Shironitsev, RU) |
Correspondence
Address: |
Ilya Zborovsky
6 Schoolhouse Way
Dix Hills
NY
11746
US
|
Family ID: |
20236296 |
Appl. No.: |
10/311666 |
Filed: |
December 17, 2002 |
PCT Filed: |
June 19, 2001 |
PCT NO: |
PCT/RU01/00239 |
Current U.S.
Class: |
424/130.1 ;
424/600 |
Current CPC
Class: |
C07K 16/24 20130101;
C07K 16/248 20130101; A61P 25/18 20180101; C07K 16/249 20130101;
A61P 29/00 20180101; C07K 16/246 20130101; C07K 16/44 20130101;
A61P 25/32 20180101; A61P 3/10 20180101; A61P 31/12 20180101; A61K
2039/505 20130101; A61K 41/0004 20130101; C07K 2317/77 20130101;
A61P 43/00 20180101; A61P 25/30 20180101; A61K 2039/545 20130101;
C07K 16/241 20130101; C07K 16/243 20130101; A61P 37/00 20180101;
C07K 16/245 20130101; A61P 25/28 20180101; C07K 16/28 20130101;
A61P 31/00 20180101; C07K 16/40 20130101; C07K 2317/73 20130101;
A61P 25/24 20180101; A61P 9/10 20180101; C07K 16/00 20130101; A61P
3/04 20180101; C07K 16/26 20130101; C07K 16/2806 20130101; A61P
25/16 20180101; A61P 25/36 20180101; C07K 2317/75 20130101; C07K
16/22 20130101; A61P 9/00 20180101; A61K 39/39583 20130101; A61P
25/34 20180101; A61K 31/277 20130101 |
Class at
Publication: |
424/130.1 ;
424/600 |
International
Class: |
A61K 039/395; A61K
033/00 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 20, 2000 |
RU |
2000115594 |
Claims
1. A method of treating a pathological syndrome by administration
of activated forms of ultra-low doses of antibodies to an antigen,
wherein said activated forms are obtained by repeated consecutive
dilution combined with external treatment, and said antigen is a
substance or a pharmaceutical agent exerting influence upon the
mechanisms of formation of the pathological syndrome.
2. The method of treating a pathological syndrome described in
claim 1, wherein said activated form of ultra-low doses of
antibodies are produced by homeopathic technology.
3. The method of treating a pathological syndrome described in
claim 1, wherein said activated forms of ultra-low doses of
antibodies to an antigen or hapten are administered together with
this antigen, and said antigen or hapten is a substance or a
pharmaceutical agent exerting influence upon the mechanisms of
formation of the pathological syndrome.
4. A method of treating a pathological syndrome by administration
of activated forms of ultra-low doses of antibodies to an antigen,
wherein said pathological syndrome is caused by introduction of the
antigen, said activated forms are obtained by repeated consecutive
dilution combined with external treatment, and said antigen is a
substance or a pharmaceutical agent capable of causing intoxication
and/or addiction.
5. The method of treating a pathological syndrome described in
claim 4, wherein said activated form of ultra-low doses of
antibodies are produced by homeopathic technology.
6. The method of treating a pathological syndrome described in
claim 4, wherein said activated forms of ultra-low doses of
antibodies to an antigen or hapten are administered together with
this antigen, and said antigen or hapten is a substance or a
pharmaceutical agent exerting influence upon the mechanisms of
formation of the pathological syndrome.
7. A method of treating a pathological syndrome by administration
of activated forms of ultra-low doses of antibodies to an antigen,
wherein said activated forms are obtained by repeated consecutive
dilution combined with external treatment, and said antigen is a
hapten conjugated with high-molecular compound, wherein said hapten
is substance or a pharmaceutical agent exerting influence upon the
mechanisms of formation of the pathological syndrome.
8. The method of treating a pathological syndrome described in
claim 7, wherein said activated forms of ultra-low doses of
antibodies are produced by homeopathic technology.
9. The method of treating a pathological syndrome described in
claim 7, wherein said activated forms of ultra-low doses of
antibodies to an antigen or hapten are administered together with
this antigen, and said antigen or hapten is a substance or a
pharmaceutical agent exerting influence upon the mechanisms of
formation of the pathological syndrome.
10. A method of treating a pathological syndrome by administration
of activated forms of ultra-low doses of antibodies to an antigen,
wherein said activated forms are obtained by repeated consecutive
dilution combined with external treatment, said antigen is an
antigen of a tissue or a tissue culture, and said antigen exerts
influence upon the mechanisms of formation of pathological syndrome
predominantly in this particular tissue.
11. The method of treating a pathological syndrome described in
claim 10, wherein said activated form of ultra-low doses of
antibodies are produced by homeopathic technology.
12. A pharmaceutical agent for treating a pathological syndrome
containing an activated form of ultra-low doses of monoclonal,
polyclonal or natural antibodies, wherein said activated form is
produced by repeated consecutive dilution and external treatment
predominantly based on homeopathic technology, and said antigen is
a substance or a drug exerting influence upon the mechanisms of
formation of the pathological syndrome.
13. The pharmaceutical agent described in claim 12, wherein
antibodies are raised to substances of exogenous origin.
14. The pharmaceutical agent described in claim 12, wherein
antibodies are raised to substances of endogenous origin.
15. The pharmaceutical agent described in claim 12, wherein
antibodies are raised to antigens of fetal tissues or tissue
cultures.
16. The pharmaceutical agent described in claim 12, wherein
antibodies used are antiidiotypic antibodies.
Description
FIELD OF THE INVENTION
[0001] The invention relates to medicine and can be employed for
treating various diseases and for producing pharmaceutical
preparations possessing no side effects.
DESCRIPTION OF THE BACKGROUND ART
[0002] The use of antibodies for treating pathological syndromes is
well known (SU 1331508 A, A 61 K 39/00, 1984; SU 1730144 A1, C 12 N
7/00, 1992).
[0003] Also known are pharmaceutical preparations based on
antibodies (serums, immunoglobulins) applied in therapeutic doses
(see, for example, Register of Pharmaceutical Agents of Russia,
Encyclopedia of Drugs, 7.sup.th edition, 2000, pp.358-359).
[0004] However, the range of application of these preparations is
for the most part limited to etiological treatment of infectious
diseases, and their use may be associated with undesirable side
effects.
DESCRIPTION OF THE INVENTION
[0005] The invention is aimed at enhancing the efficacy of
treatment of pathological syndromes by the use of antibodies in
activated forms for fundamentally new indications--to control a
pathological syndrome; it is also intended for producing
pharmaceutical substances without marked side effects.
[0006] For solution of the given problem, the method for treating a
pathological syndrome includes administration of activated forms of
ultra-low doses of antibodies to an antigen, wherein said activated
forms are obtained by repeated consecutive dilution combined with
external treatment, and said antigen is a substance or a
pharmaceutical agent implicated in or exerting influence upon the
mechanisms of formation of the pathological syndrome; said antigen
can also represent a substance (or drug) that is, upon its
introduction into the body, with non-medical purposes included, can
act as direct cause of the pathological syndrome.
[0007] To this end it is expedient to use ultra-low doses of
antibodies in activated forms prepared by homeopathic technology of
potentiation (dynamization).
[0008] Activated forms of ultra-low doses of antibodies to a
substance or a pharmaceutical agent can be also introduced together
with this very substance or pharmaceutical agent implicated in or
exerting influence upon the mechanisms of the pathological syndrome
or directly causing the pathological syndrome.
[0009] Besides, the objective is also accomplished by a
pharmaceutical agent containing activated forms of ultra-low doses
of monoclonal, polyclonal or natural antibodies to an antigen,
wherein said activated forms are produced by repeated consecutive
dilution and external treatment predominantly based on homeopathic
technology, and said antigen is a substance or a pharmaceutical
agent exerting influence upon regulation of the impaired
function.
[0010] At that, antibodies used in activated (potentiated) forms of
ultra-low doses are raised against antigens of exogenous or
endogenous origin, against autologous antigens, fetal antigens;
anti-idiotypic antibodies are used too.
[0011] The drugs (pharmaceutical agents) obtained in accordance
with the present invention constitute a novel class of
pharmacological preparations, distinctive in combination of
specific pharmacological activity, stable therapeutic action free
from side effects, ecological purity and low prime cost.
EMBODIMENTS OF THE INVENTION
[0012] The pharmaceutical preparation can be prepared in the
following way.
[0013] 1. Obtaining of Antibodies.
[0014] Polyclonal antibodies specifically binding to compounds of
various classes: proteins, polynucleotides, oligosaccharides,
glycolipids, etc. and interacting with low-molecular substances
(haptens) are obtained through active immunization of animals. For
this purpose, animals are given a series of antigen injections
according to a specially designed pattern, the antigen being either
an individually isolated high-molecular substance, or a synthetic
conjugate (for haptens). This procedure results in obtaining a
monospecific antiserum with high content of antibodies apt for
further processing. If necessary the antibodies present in the
antiserum are purified. Fractionating by salt precipitation or ion
exchange chromatography is used for this purpose.
[0015] Monoclonal antibodies of different specificity interacting
both with low-molecular haptens and with epitopes of high-molecular
substances are obtained by means of hybridome technology. At that,
the initial stage of the process includes immunization based on the
principles already developed for preparation of polyclonal
antiserums. Further stages of work envisage yielding
antibody-producing clones of hybrid cells, produced antibodies
being of identical specificity. Their isolation is carried out with
the same methods as for polyclonal antiserums.
[0016] Natural antibodies to exogenous antigens and biological
regulators of various origin are isolated from human blood serum by
the method of affinity chromatography. To this end, a carrier with
a covalently bound antigen, either a hapten or a high-molecular
compound is used as an immunosorbent. Chromatography yields
antibodies with narrow specificity and affinity.
[0017] Methods of obtaining antibodies are described, for example,
in the book Immunological Methods, under the editorship of G.
Frimel, Moscow, Medicina Publishing House, 1987, p.9-33).
[0018] Isolated antibodies to a substance or a pharmaceutical agent
are consecutively repeatedly diluted and exposed to external
treatment until ultra-low or low doses are obtained, for example,
in accordance with homeopathic technology of potentiation
(dynamization) (see V. Shvabe, Homeopathic Pharmaceutical Agents. A
Manual on Description and Preparation, Moscow, 1967, p.12-38). At
that, the concentration is proportionally reduced through
consecutive dilution of 1 volumetric part of the initial substance
(antibodies) in 9 volumetric parts (for decimal dilutions, D) or in
99 volumetric parts (for centesimal dilutions, C) of a neutral
solvent until the required dose (potency) is obtained; each
dilution is followed by multiple vertical mechanical shaking; for
each dilution separate vessel is preferable.
[0019] External treatment in the process of dilution can also be
performed by sound generator or other mechanical or electromagnetic
action.
[0020] The pharmaceutical preparation thus yielded is used for the
most part in dosage forms and dilutions common for homeopathic
practice, such as alcoholic or aqueous solutions or tablets
(granules) obtained by saturating the excipient of the formulation
with potentiated solution or by direct introduction of the latter
into liquid dosage form of the preparation.
[0021] An example of obtaining a pharmaceutical preparation in form
of activated polyclonal antibodies (antiserum) to morphine is given
below.
[0022] 1. Obtaining Morphine-ovalbumin Conjugate.
[0023] Solution of 50 mg (0.001 mmol) ovalbumin in 5.0 ml of
distilled water was mixed with 2.0 ml dimethylformamide containing
15.0 mg (0.039 mmol) of morphine 6-hemisuccinate and while the
mixture was cooling the solution of 15 mg (0.055 mmol) of
water-soluble carbodiimide in 3 ml of distilled water was added to
it by drops. The reaction mixture was incubated for 5 hours at
4.degree. C. The yielded conjugate was isolated by gel
chromatography on Sephadex G25 column and exposed to
lyophilization.
[0024] The quantity of conjugated morphine was calculated from
UV-spectra of the original protein and the yielded conjugate by
changes in absorption at 280 nm. According to UV-spectra, the
synthesized conjugate contained 12-15 moles of hapten per mole of
protein.
[0025] 2. Obtaining a Monospecific Antiserum to Morphine-ovalbumin
Conjugate.
[0026] Immunization of Viennese Blue rabbits weighing not more than
2 kg was performed in cycles with a 10-day interval between them.
The maximal number of injections was four. The conjugate was
injected into the area of periarticular lymph nodes of front and
hind paws in the dose of 1 mg per immunization. To this end the
antigen was previously diluted in 1 ml of complete Freund's
adjuvant. The total volume of immunization mixture was 2 ml.
[0027] Subsequent immunizations were performed using incomplete
Freund's adjuvant, adhering to the above-mentioned proportions of
antigen and adjuvant. A test blood sample was drawn from marginal
ear vein of the animal 10 days after immunization.
[0028] The rabbit blood serum was obtained by centrifugation at 100
g for 10 minutes at room temperature; after that chloroform was
added as a preservative its final concentration reaching 13%.
[0029] The antiserum obtained was tested for specific antibodies to
morphine by means of enzyme immunoassay, the antibodies being
detected with conjugate of enzyme-labeled anti-species
(anti-rabbit) antibodies.
[0030] Thus obtained antiserum contained specific antibodies active
in the dilution 1:1000-1:25000.
[0031] Further on, .gamma.-globulin fraction was isolated from the
yielded antiserum. To this end the protein was precipitated with
50% ammonium sulfate with subsequent rinsing of the precipitate
with 30% saline solution, centrifugation and dialysis against
phosphate buffer. The fraction thus prepared contained specific
antibodies to morphine and was then used for producing the
pharmaceutical preparation.
[0032] 3. Obtaining the Activated Form (Ultra-low Dose) of the
Antibodies to Morphine.
[0033] Antiserum .gamma.-globulins (0.5 ml) was placed into
E-6.sub.1 vessel and mixed with 4.5 ml of distilled water; the
mixture was shaken 10 times yielding 5 ml of the first centesimal
dilution. The first centesimal dilution (0.05 ml) was placed into
E-6.sub.2 vessel with 4.95 ml of distilled water; the mixture was
shaken 10 times yielding 5 ml of the second centesimal dilution.
The centesimal dilutions from the third to the twenty-ninth were
prepared in a similar fashion. The thirtieth centesimal dilution
was prepared by solving the twenty ninth one in 20% solution of
ethanol. The yielded alcoholic solution was used for treatment
purposes.
[0034] Examples of use of activated forms of ultra-low doses of
antibodies conventionally designated as potentiated (dynamized)
antibodies (by analogy with terminology used in homeopathic
literature) for treatment of various pathological syndromes are
given below.
EXAMPLE 1
Potentiated Antibodies to Hypnotic Medications
[0035] A. Patient I., aged 46, a high school instructor, had long
been suffering from insomnia manifested by difficulties in falling
asleep. The patient had a history of hepatitis (hepatitis and
impaired metabolism of xenobiotics in the liver resulting from it
probably accounted for the aftereffects of the preparation). For
the last six months the patient had been taking 7.5 mg of IMOVAN at
bedtime 2-3 times a week; in the morning he suffered from
drowsiness and dizziness. The dose reduced to 1/2 tablet did not
produce the desirable somniferous effect. The treatment with
antibodies to IMOVAN C200 in tablets was started after
discontinuation of IMOVAN intake. Two weeks later dizziness and
morning drowsiness disappeared. The patient's sleep became
normal.
[0036] B. Patient P., aged 62, complained of a sleeping disorder:
awakening at 2-3 a.m. The patient had been using barbiturate
derivatives as somniferous medications but abandoned these drugs
because of their decreasing efficiency. The patient was recommended
to take 10 drops of a 25% alcohol solution of potentiated
monospecific antiserum to MIDAZOLAM (dormicum, flormidal,
8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-
-a][1,4]benzodiazepine hydrochloride) at bedtime. Three days after
the beginning of the treatment the patient stated that he was
easier falling asleep; the sleep duration extended to 7. A
continued intake of the preparation was recommended.
[0037] C. Patient Ch., aged 42, was admitted to hospital in the
condition of moderate alcohol intoxication. Next morning the
patient complained of tremor and disorders in coordination of
movements. After a single dose of 15 ml of an aqueous solution of
potentiated monoclonal antibodies to NITRAZEPAM (radedorm,
1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepine-- 2-one) C30 the
patient fell asleep. This suggested a conclusion that the
preparation was efficient in restoration of sleep in the process of
arresting alcohol abstinence syndrome.
[0038] D. Patient R., aged 48, a driver by profession, presented
complaints of sleeping disorders due to overfatigue. An intranasal
administration of 0.5 ml of a potentiated aqueous solution C20 of
antibodies to ZOLPIDEM
(N,N,6-trimethyl-2-(4-methylphenyl)imidazolo[1,2-a- ]pyridine
acetamide) at bedtime was suggested for controlling his insomnia.
At a new visit 5 days later the patient stated normalization of his
sleep. Examination did not reveal any depression of reflexes or
muscle tone. This suggested a conclusion that this preparation can
be prescribed to the patients whose professional activities require
precise coordination of movements.
[0039] E. Patient M., aged 54, complained of drowsiness and
disorders in coordination of movements and presented a long-time
history of the use of somniferous medications. After a 7-day course
of treatment with potentiated solution of monoclonal antibodies to
ZOPICLON (imovan)
(6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo-[3,4-b]-pyrazine-5-
-ylic ester of 4-methyl-1-piperazine carboxylic acid) C50 in a dose
of 1 tablet twice a day the enhancement of motor activity and sleep
normalization were observed.
EXAMPLE 2
Potentiated Antibodies to Anesthetic Drugs
[0040] A. Patient M., aged 36, complained of nausea after the
operation (appendectomy). For anesthesia THIOPENTAL SODIUM
(monosodium salt of
5-ethyldihydro-5-(1-methylbutyl)-2-thiooxo-4,6-(1H,5H)-pyrimidinedione)
had been used. An oral intake of 20 ml of a C30 homeopathic
dilution of the antiserum to thiopental 3 times a day was
prescribed, which made it possible to attenuate nausea.
[0041] B. Patient P., aged 28, complained of cramps in his lower
extremities and hypertonicity of the gastrocnemius muscles. An oral
intake of 15 ml of a C200 dilution of potentiated antiserum to
SODIUM OXYBUTIRATE (sodium salt of 4-hydroxybenzoic acid) at
bedtime was prescribed. The examination conducted 5 days later
showed diminution of muscular tonicity.
[0042] C. Patient M., aged 6, was admitted to the
otorhinolaryngologic unit for a postoperative check-up after
tonsillectomy. An oral administration of a C30 solution of
potentiated antibodies to KETAMINE
[(+-)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
hydrochloride] made it possible to reduce the sensitivity of the
child's mucosa and to perform an examination.
[0043] D. Patient A., aged 47, complained of hiccup and tachycardia
after administration of ETHOMIDATE (ethyl ester of
(R)-1-(1-phenylethyl)-1H-imi- dazole-5-carboxylic acid). A single
oral dose of 50 ml of a homeopathic C30 solution of monoclonal
antibodies to ethomidate was administered. Thirty minutes later
hiccup disappeared and the cardiac rhythm was back to normal.
[0044] E. Patient D., aged 68, was admitted to a surgical hospital
for a scheduled operation on benign prostatic hyperplasia. Three
years earlier he had undergone an operation for urolithiasis under
HALOTHANE (1,1,1-trifluoro-2-chloro-2-bromoethane) anesthesia. The
postoperative period was complicated by liver function disorders
manifested by dyspepsia, hyperbilirubinemia, and positive liver
function tests. The patient presented a history of poor tolerance
of other anesthetics. Therefore, slow intravenous infusion of 3 ml
of potentiated antibodies to HALOTHANE dissolved in a 5% glucose
solution was used for anesthetic purposes. The operation and the
postoperative period showed no complications.
EXAMPLE 3
Potentiated Antibodies to Anticonvulsant Drugs
[0045] A. Patient B., aged 19, has been suffering from generalized
epilepsy (grand mal seizures combined with psychomotor symptoms)
since the age of 5. TEGRETOL (5-carbamoyl-5H-dibenz(b,f)azepine)
chosen by the trial-and-error method had proved to be the most
efficient anticonvulsant drug for the patient; she had been
receiving a dose of 0.2 mg (1 tablet) 3 times a day for 2 years.
The patient's mother consulted the attending doctor at to multiple
bruises having appeared on the patient's body in the course of the
last 10 days without any preceding mechanical trauma. Total blood
test revealed a depressed white blood (2.9.times.10.sup.3/.mu- .l)
and platelet count (100.times.10.sup.3/.mu.l). The treatment with
C30 potentiated monoclonal antibodies to the dibenzoazepine group
forming the basis of the drug molecule was started whereas TEGRETOL
was discontinued. Two weeks later the blood pattern was back to
normal, no epileptic seizures were registered.
EXAMPLE 4
Potentiated Antibodies to Antiparkinsonian Drugs
[0046] A. Patient Z., aged 37, developed parkinsonian symptoms
after vernal encephalitis. The patient had been taking daily 10 mg
(4 tablets) of BROMOKRYPTINE (2-bromo-.alpha.-ergokryptine) with
good effect but complained of excessive fatigue, headaches, and
constipation. The treatment with potentiated antibodies to
2-bromo-.alpha.-ergokryptine (a C1000 dilution) in a daily dose of
1 tablet taken in the morning was started. Three weeks later the
bowel function was back to normal and headaches subsided; however,
complaints on excessive fatigue persisted.
[0047] B. Patient E., aged 72, was on LEVODOPA
(3-hydroxy-1-tyrosine) for Parkinson's disease. He complained of
nausea and vomiting. Antiemetic drugs of the phenothiazine group
with smaller doses of LEVODOPA lead to the exacerbation of his main
disease. The use of a C200 dilution of polyclonal potentiated
antibodies to LEVODOPA in a dose of 1 tablet twice a day improved
the patient's tolerance to the preparation.
EXAMPLE 5
Potentiated Antibodies to Neuroleptics
[0048] A. Patient E., aged 42, was admitted to a
psycho-neurological dispensary in a condition of psychomotor
agitation due to alcohol intoxication. Fifteen minutes after
intravenous administration of 1 ml of a C30 aqueous solution of
potentiated antiserum to HALOPERIDOL
(4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-buta-
none decanoate) in a 5% glucose solution the agitation arrested and
the patient went to sleep.
[0049] B. Patient L., aged 50, consulted her physician for
disordered coordination of movements. The examination revealed
inhibited reflexes in her low extremities, namely the knee-jerk and
the Achilles tendon reflexes. She presented a long-time (1.5
months) history of FLUPHENAZINE (moditene) intake. The discontinued
use of the preparation was combined with an intranasal
administration of a C30 aqueous solution of monoclonal antibodies
to fluphenazine (4-[3-[2-(trifluoromethyl)-10H-phenothiazine-1-
0-yl]propyl]-1-piperazinylethanol) and a once-a-day slow
intravenous administration of a dose of 1 ml. Four days later the
patient's gait was back to normal and the muscle tone of her low
extremities increased.
[0050] C. Patient R., aged 62, complained of restlessness and
groundless night fears. Earlier she sought for physician's advice
for insomnia and used to take radedorm for it. Oral administration
at bedtime of the antiserum to AZALEPTINE (clozapine, leponex)
(8-chloro-11-(4-methyl-1-pip-
erazinyl)-5H-dibenzo[b,e][1,4]diazepine) in a form of 10 ml of a
C200 homeopathic solution was prescribed. Seven days later phobias
disappeared and the sleep became normal.
[0051] D. Patient Ch., aged 45, complained of tremor and disordered
coordination of movements. He had a long-time history of
neuroleptic drugs intake (haloperidol, aminazine) for
schizophrenia. Oral administration of 5 ml of a C30 dilution of
homeopathic solution of monoclonal antibodies to RISPERIDONE
(3-[2-[4-(6-fluoro-1,2-benzisoxazol--
3-yl)piperidino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimid-
in-4-one) twice a day by intramuscular injections was prescribed.
Repeated examination 7 days later revealed absence of tremor and a
tendency to normalization of the patient's gait. No psychotic
disorders were observed.
[0052] E. Patient S., aged 29, suffered from depressive-paranoid
form of schizophrenia. He had been taking neuroleptic drugs of the
phenothiazine series for some years; the best clinical effect was
noted in TISERCINE
(2-methoxy-10-(3-dimethylamino-2-methylpropyl)-phenothiazine
hydrochloride). During last 4 months the patient himself and his
relatives drew their attention to the aggravation of extrapyramidal
disorders and impaired bowel function (constipation). Total blood
rest revealed depressed white blood count reaching the lower bound
of normal (3.8.times.103/.mu.l). The use of a C1000 dilution of
potentiated monoclonal antibodies to PHENOTHIAZINE in a dose of 1
tablet 3 times a day for 20 days (with discontinued tisercine
intake) resulted in a marked relaxation of extrapyramidal disorders
and normalization of the bowel function; the patient's white blood
count increased to 4.7.times.103/.mu.l. No psychotic disorders were
present. The patient's sleep, appetite and mood were within normal
limits.
[0053] F. Patient F., aged 19, suffered from oligophrenia in the
form of idiocy; aggressive behavior. She received a maintaining
dose of HALOPERIDOL
(4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluoroph-
enyl)-1-butanone decanoate) (20 mg daily) and displayed marked
extrapyramidal disorders. The lowering of the dose resulted in the
enhancement of the patient's aggressiveness. The use of a C30
dilution of polyclonal potentiated antibodies to butyrophenone in a
dose of 1 tablet twice a day improved the tolerance of HALOPERIDOL
and made it possible to reduce the dose to 5 mg a day and
subsequently to maintain the patient in a satisfactory condition by
administering the potentiated preparation alone.
EXAMPLE 6
Potentiated Antibodies to Minor Tranquilizers
[0054] A. Patient V., aged 50, a research worker, has been
receiving a day-time tranquilizer, MEZAPAM, for his
obsessive-compulsive neurosis. He complained of drowsiness
(probably caused by impaired detoxifying function of his liver).
The use of a C30 dilution of potentiated polyclonal antibodies to
the benzodiazepine nucleus made it possible to replace the
tranquilizer. The patient's condition became satisfactory; no
neurotic disorders were noted.
[0055] B. Patient E., aged 71, complained of restlessness and
insomnia. Oral administration of a C200 preparation of potentiated
polyclonal antibodies to DIAZEPAM
(7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-ben-
zodiazepine-2-one) in a dose of 1 tablet 3 times a day was
prescribed. Four days later the district physician noted
normalization of sleep along with fewer complaints of
restlessness.
[0056] C. Patient S., aged 30, registered in a psycho-neurological
dispensary, complained of the onset of restlessness, anxiety, and
insomnia after the withdrawal of PHENAZEPAM. Oral intake of the
homeopathic solution of antiserum to 2H-1,4-benzodiazepine twice a
day was prescribed. After two days of treatment the normalization
of sleep and mood were noticed. The general state of health was
satisfactory and no anxiety was observed.
[0057] D. Patient I., aged 39, complained of fatigability,
disorders in coordination of movements, and restlessness.
Examination revealed no organic disorders of the central nervous
system. After the diagnosis of neurasthenia was established a
course of treatment with a C12 homeopathic solution of polyclonal
antibodies to PHENIBUT (.gamma.-amino-.beta.-pheny- lbutyric acid
hydrochloride) was suggested. After 2 days of oral intake (1 tablet
twice a day) of the preparation tremor subsided and sleep became
normal.
EXAMPLE 7
Potentiated Antibodies to Antidepressants
[0058] A. Patient V., aged 36, complained of the worsening of mood
and sleeping disorders in form of early awakening along with
difficulties in falling asleep. The patient also stated
irritability and tremor without objective reason. An intranasal
administration of 5 drops of a C30 homeopathic solution of
antiserum to FLUOXETIN (PROZAC)
(+-)-N-methyl-.gamma.-[4-(trifluormethyl) phenoxy]
benzolpropanamine) 3 times a day was recommended. Upon a new
examination 5 days later the patient stated the betterment of his
mood along with a tendency to normalization of sleep. The
physician's recommendation was to continue the course of
treatment.
[0059] B. Patient K., aged 39, complained of insomnia, tremor,
restlessness, and impaired ability to work. He received a course of
treatment with a C1000 dilution of potentiated polyclonal
antibodies to FLUVOXAMINE
((E)-5-methoxy-1-[4-(trifluormethyl)phenyl]-1-pentanone-O-(2--
aminoethyl)oxime) in an oral dose of 1 tablet 4 times a day. After
3 days of regular drug intake the normalization of sleep was
observed along with the improvement of mood and control of
restlessness.
[0060] C. Patient Sh., aged 56, complained of restlessness, feeling
of fear, and sleep disorders. An intranasal administration of 1 ml
of a 2% C30 solution of antiserum to AMITRIPTYLINE
(3-(10,11-dihydro-5H-dibenz[a,-
d]-cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine) 3 times a day
was recommended.
[0061] Upon a new examination 3 days later the patient stated the
normalization of sleep along with the reduction in the frequency
and intensity of his fits of phobia. He was advised to continue
this treatment; high efficacy of the drug in this particular case
was noted.
[0062] D. A young man aged 18 had been suffering from enuresis
since his childhood. AMITRIPTYLINE was found to have a good effect
upon him. After three weeks of treatment the patient's relatives
noticed his drowsiness, the patient himself complained of visual
disorders (impaired accommodation) and bouts of arrhythmia from
time to time. A C50 dilution of potentiated monoclonal antibodies
to the tricyclic group, constituting the nucleus of tricyclic
antidepressants was prescribed in a dose of 1 tablet twice a day.
The symptoms of side effects disappeared whereas the curative
action persisted.
[0063] E. Patient Ch., aged 32, a manager, presented a vast number
of complaints among which the dominating were constant tiredness,
poor sleep with no refreshing effect, reduced ability to work,
depression, constipation along with joint and muscle aches. This
condition had been lasting for more than half a year. A thorough
clinical and laboratory examination revealed no psycho-neurological
or somatic lesions that would account for such syndromes. The
diagnosis of a chronic fatigue syndrome was established. A month of
combined therapy including physiotherapy, vitamin therapy, and
antidepressant IMIPRAMINE intake resulted in a mild positive
effect. The treatment with a C200 dilution of potentiated
antibodies to IMIPRAMINE in a dose of 1 tablet 3 times a day was
begun. A week later a marked improvement in the patient's condition
was noted; his ability to work increased and the number of
complaints declined.
[0064] F. Patient K., aged 29, was admitted to a
psycho-neurological hospital with an established diagnosis of
manic-depressive psychosis in the phase of exacerbation. During
examination the patient complained of the lack of motivations and
tearfulness; the patient was not active physically. He used to take
amitriptyline and diazepam for a long time. An oral intake of a
C1000 solution of the antiserum to MOCLOBEMIDE (aurorix)
(p-chloro-N-(2-morpholinoethyl)-benzamide) in the form of 5 ml of
the aqueous solution 2 times a day was prescribed. A new
examination 4 days later showed that the patient became more
compliant; improved mood and enhanced liveliness were reported. A
conclusion was drawn that the therapy was efficient.
[0065] G. Patient C., aged 49, suffered from depression and
sociophobia; he had been receiving daily 225 mg of MOCLOBEMIDE
(aurorix) (1.5 tablets in three doses). Despite his attending
physician's warnings the patient sometimes broke his diet. Twice
after eating a cheese sandwich and a pizza with cheese he had
episodes of hypertension, his blood pressure reaching 190/110 mm
Hg. With moclobemide discontinued, a C30 dilution of potentiated
polyclonal antibodies to moclobemide was administered in a dose of
1 tablet once a day. Further on, the treatment was well tolerated
and depression symptoms subsided rapidly.
[0066] H. Patient S., aged 44, developed fluctuations of mood,
tearfulness, and low vital activity caused by the climacteric
period. Her psychiatrist estimated these symptoms as manifestations
of a depressive syndrome. The use of traditional antidepressants
caused somnolence and lethargy interfering with her professional
duties. The prescription of a C12 dilution of potentiated antiserum
to CERTRALINE purified by affinity chromatography in a dose of 1
tablet twice a day resulted in a rapid improvement of he patient's
general state and stabilization of her mood.
EXAMPLE 8
Potentiated Antibodies to Antiemetic Drugs of Central Action
[0067] A. Patient Zh., aged 64, developed nausea and vomiting
during the course of radio- and chemotherapy for peripheral lung
cancer. The prescription of MOTILIUM controlled manifestations of
dyspepsia but caused weakness, somnolence and intestinal cramps.
With MOTILIUM discontinued, the administration of 1 ml of a C6
dilution of potentiated antibodies to MOTILIUM in the form of
intramuscular injections twice a day resulted in the disappearance
of neurotoxic and spastic reactions. The use of the preparation was
continued with a positive clinical effect.
EXAMPLE 9
Potentiated Antibodies to Central-action Muscle Relaxants
[0068] A. Patient B., aged 25, developed contractures of his lower
extremities after a spinal trauma. MYDOCALM
(1-piperidino-2-methyl-3-para- -tolylpropanone-3hydrochloride) in a
dose of 300 mg a day was prescribed. After a favorable initial
effect the patient noticed a gradual increase in the muscular
tension in his lower extremities along with systemic arterial
hypotension (105/60 mm Hg) after 2 months of the treatment. The
prescription of a C200 dilution of potentiated antibodies to
MYDOCALM in a dose of 1 tablet twice a day resulted in the
normalization of arterial blood pressure (120/70) as well as in the
reduction of muscular tension. The antibody therapy made it
possible to reduce the dose of MYDOCALM by 25%.
EXAMPLE 10
Potentiated Antibodies to Choline Esterase Inhibitors
[0069] A. Patient P., aged 20, with an established diagnosis of
congenital myasthenia took UBRETIDE
(3-oxy-1-methylpyridinium-hexamethylene-bis-(N-m- ethylcarbamate)
dibromide) (the maintaining dose was 1 tablet every other day). She
started complaining of excessive salivation and abdominal cramps.
The use of a D6 dilution of potentiated antibodies to UBRETIDE in a
daily morning dose of 1 tablet improved the patient's tolerance of
UBRETIDE without reducing its efficacy and later made it possible
to switch to therapy with the potentiated preparation only.
EXAMPLE 11
Potentiated Antibodies to Psychostimulants and Nootropic Drugs
[0070] A. Patient M., aged 58, complained of memory disorders and
insomnia. An oral intake of 20 drops of an alcohol solution of
antibodies to NOOTROPIL (pyracetam) (2-oxo-1-pyrrolidinylacetamide)
in a potency of C200 at bedtime was prescribed. During her second
visit 7 days later the patient reported of an extended duration of
sleep along with less difficulties in falling asleep. The
recommendation was to continue the course of treatment.
[0071] B. Patient M., aged 43, was admitted to hospital in the
state of alcohol withdrawal. The next day he started complaining of
restlessness and tremor. A C30 dilution of potentiated antiserum to
AMINALON (gammalon) (4-aminobutyric acid) in a dose of 1 tablet 6
times a day was prescribed. The reduction of tremor and the
improvement of mood were noted. After 2 days of therapy the patient
was discharged in a satisfactory condition.
[0072] C. Patient S., aged 72, complained of tachycardia and
sleeping disorders; she presented a long-time (3 weeks) history of
SYDNOCARB (3-(.alpha.-methylphenyl)-N-phenyl-carbamoylsydnonimine)
intake. The intranasal administration of 10 drops of a C15 solution
of monoclonal antibodies to SYDNOCARB 3 times a day was prescribed.
An examination after 5 days of treatment revealed the absence of
tachycardia; the patient reported of less difficulties in falling
asleep.
[0073] D. Patient V., aged 65, with an established diagnosis of
asthenic syndrome as a remote consequence of a cranio-cerebral
trauma had been taking MOLSIDOMINE (ethyl ester of
N-carboxy-3-morpholino-sydnonimine) in a dose of 1 tablet 3 times a
day (6 mg per diem) to prevent fits. She sought her physician's
advice for headaches and worsening of sleep. After MOLSIDOMINE
withdrawal the treatment with C30 dilution of potentiated
monoclonal antibodies to the sydnonimine group in a dose of 1
tablet in the morning was started. The favorable effect of the
treatment has been lasting for 6 months.
[0074] E. Patient D., aged 38, complained of fatigability,
weakness, and headaches. The oral intake of 10 ml of a C40 dilution
of potentiated polyclonal antibodies to CAFFEINE
(1,3,7-trimethylxanthine) 3 times a day was prescribed. At his
second visit to the physician 7 days later the patient pointed to
easier awakening and the disappearance of headaches. He was
recommended to continue the course of treatment.
[0075] F. Patient P., aged 35, a journalist by profession,
presented symptoms of caffeine addiction: he had to drink up to
12-15 cups of strong coffee to keep himself active. The patient was
emotionally labile, inclined to overestimating his own personality,
and complained of poor sleep. He also had a pronounced tremor of
his hands. The use of a C200 dilution of potentiated antibodies to
CAFFEINE (1,3,7-trimethylxanthine) in a dose of 1 tablet 3 times a
day resulted in the reduction of the amount of consumed coffee to
4-5 cups, the improvement of sleep, the disappearance of tremor,
and better mood. Now the patient is active and manifests high
working efficiency.
[0076] G. Patient R., aged 78, is on regular treatment with
PYRACETAM (nootropil) (2-oxo-1-pyrrolidinylacetamide) in a daily
dose of 1.6 g for Alzheimer's disease. The general effect of the
treatment being favorable, the patient's relatives noticed
enhancement of the patient's sexual activity manifested by his
inappropriate behavior. The substitution of pyracetam by a C200
dilution of potentiated antibodies to PYRACETAM made it possible to
get rid of sexual disinhibition while preserving the nootropic
effect.
[0077] H. Patient G., aged 4, suffered from mental retardation due
to a birth trauma. A 4-week course of everyday injections of
CEREBROLYSINE (a complex of peptides isolated from pig brain)
resulted in some improvement of the child's cognitive activity.
During repeated courses of treatment cerebrolysin was substituted
by a C50 dilution of potentiated polyclonal antibodies to it (in a
dose of 1 tablet 2 times a day). The patient's memory became much
better as well as her abilities to develop and maintain skills.
EXAMPLE 12
Potentiated Antibodies to Preparations Improving Cerebral
Circulation
[0078] A. Patient L., aged 54, presented a history of cerebral
atherosclerosis and an ischemic stroke a month ago. He was treated
with HALIDOR (1-benzyl-1-(3-dimethylaminopropoxy)-cycloheptane
fumarate) in tablets (100 mg twice a day). The patient complained
of sleeping disorders and tachycardia (92 beats/min). The use of a
C30 dilution of potentiated antibodies to HALIDOR (in a daily dose
of 1 tablet within a month) improved his sleep; his heart rate went
down to 76-80 beats/min.
EXAMPLE 13
Potentiated Antibodies to Analeptic Drugs
[0079] A. Patient T. aged 15, was admitted in the state of alcohol
intoxication. Examination revealed hypotension (90/60 mm Hg),
bradycardia, and nausea. The intranasal administration of 1 ml per
hour of a C200 dilution of antiserum to CORDIAMINE
(N,N-diethyl-3-pyridinecarb- oxamide) was prescribed. After 6 hours
of the treatment nausea disappeared and the patient's blood
pressure was back to normal.
EXAMPLE 14
Potentiated Antibodies to Anticonvulsant (Antiepileptic) Drugs
[0080] A. Patient D., aged 58, complained of tonic cramps in her
lower extremities. The oral intake of calcium gluconate in
combination with 10 ml of a D12 homeopathic solution of antibodies
to DEPAKIN (SODIUM VALPROATE) (sodium 2-propylvalerate) at bedtime
was recommended. The reduction of convulsive reactions was stated
after 2 days of the therapy.
[0081] B. Patient E., aged 47, was admitted to the in-patient unit
of the hospital because of the exacerbation of lumbosacral
radiculitis. Within the framework of combined therapy he received,
along with conventional anti-inflammatory therapy, a 25% intranasal
alcohol solution (a C30 dilution) of monoclonal antiserum to
FINLEPSIN (TEGRETOL) (5H-dibenz[b,f]azepin-5-carboxamide) in the
form of 10 drops per dose. The next day the pain subsided and the
excessive tension of back muscles reduced.
[0082] C. Patient T., aged 64, complained of insomnia and night
cramps in his extremities. Within the framework of combined therapy
he was receiving orally at bedtime 20 ml of a C30 dilution of
potentiated antiserum to PHENOBARBITAL (5-ethyl-5-phenyl-2,4,6(1H,
3H, 5H)-pyrimidinetrione). At his new visit to the physician 10
days later the normalization of sleep was noted along with a
reliable reduction in the frequency of convulsive reactions.
[0083] D. Patient I., aged 45, with an established diagnosis of
generalized form of epilepsy had to give up taking LAMOTRIGINE
(6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine) because of
nausea. The prescription of a C30 homeopathic solution of
monoclonal antibodies to LAMOTRIGINE in the form of 10 intranasal
drops 3 times a day instead of LAMOTRIGIN made it possible to
eliminate nausea and proceed with the course of treatment. There
have been no generalized epileptic fits in the course of 3-months'
observation.
[0084] E. Patient U., aged 39, with an established diagnosis of
epilepsy with rare absences was on PHENYTOINE
(5,5-diphenyl-2,4-imidazolidinedione- ) treatment. She complained
of dizziness and tremor for which reason and the use of the
preparation was discontinued. Instead the oral intake of 20 ml of a
D6 dilution of a potentiated antiserum to phenytoine 3 times a day
was prescribed. Two days later the patient felt better and her
tremor disappeared. No absences were registered within 8 weeks of
observation.
[0085] F. Patient P., aged 49, complained of pain and tension in
her gastrocnemius muscles. She gave a history of sciatic neuralgia.
In order to reduce the patient's muscular tension the physician
prescribed an oral intake of 20 ml of a C30 homeopathized solution
of monoclonal antibodies to BACLOPHEN
(.beta.-(aminomethyl)-4-chlorobenzenepropanoic acid) 3 times a day
in combination with anti-inflammatory therapy. At the new visit 7
days later she stated that her muscular rigidity and pain
subsided.
EXAMPLE 15
Potentiated Antibodies to Antiparkinsonian Drugs
[0086] A. Patient D., aged 76, with an established diagnosis of
Parkinson's syndrome was taking a course of treatment with LEVODOPA
(3-hydroxy-L-tyrosine). As the treatment was not very efficient,
the additional oral intake of a C15 dilution of monoclonal
antibodies to LEVODOPA was prescribed in a dose of 1 tablet 3 times
a day. The elimination of tremor was registered 3 days later, which
made it possible to conclude that the therapy became more
efficient. Three months later the patient was completely switched
to therapy with antibodies. The tremor is insignificant. The
general condition of the patient is satisfactory.
[0087] B. Patient K., aged 69, with an established diagnosis of
Parkinson's syndrome due to atherosclerosis of cerebral vessels
complained of nausea after the intake of SELEGILINE (DEPRENYL)
((R)-N,.alpha.-dimethyl-N-2-propinylbenzene ethanamine). The
intranasal administration of 10 drops of a D24 dilution of
homeopathic solution of antibodies to
(R)-N,.alpha.-dimethyl-N-2-propinylbenzene ethanamine 3 times a day
made it possible to eliminate nausea and to continue the course of
treatment with antibodies as monotherapy.
EXAMPLE 16
Potentiated Antibodies to Preparations Used Predominantly for the
Treatment of the State of Dependence
[0088] A. Patient B., aged 41, had been taking a course of
treatment in order to get rid of his habit of smoking. The
intranasal administration of 20 drops of a C1000 dilution of the
antiserum to NICOTINE (S)-3-(1-Methyl-2-pyrrolidinyl)pyridine) 2
times a day was prescribed. The patient stated the lessening of his
attraction to smoking after 4 days of the treatment with the
preparation.
[0089] B. Patient D., aged 19, was admitted to hospital on a
suspicion of drug addiction. Two hours after the oral
administration of 3 ml of a C50 homeopathic solution of antibodies
to NALOXONE (5-.alpha.)-4,5-epoxy-3,14-
-dihydroxy-17-(2-propenyl)morphinan-6-one hydrochloride) the
development of the withdrawal syndrome was registered, which was
regarded as the naloxone-like effect. The further treatment with
potentiated antibodies within the framework of combined
disintoxication therapy made it possible to arrest the state of
abstinence within 4 days.
[0090] C. Potentiated antibodies to DISULFIRAM (antabuse,
(tetraethylthio-peroxydicarbodiamide)
[0091] Patient E., aged 56, was admitted to the in-patient unit of
a hospital with low blood pressure (80/50 mm Hg), suffering from
nausea. He presented a history of alcohol intake against the
background of ESPERAL (DISULFIRAM) treatment. Five hours after the
intranasal administration of 2 ml of a C30 solution of potentiated
antibodies to DISULFIRAM the normalization of the patient's blood
pressure and the control of nausea were achieved; however,
vegetative disorders reappeared when the alcohol test was
performed.
EXAMPLE 17
Potentiated Antibodies to Narcotic Analgesics
[0092] A. Patient Ch., aged 22, was admitted to the in-patient unit
with signs of heroin withdrawal. In order to control his pain
syndrome intramuscular injections of 1 ml of a C50 dilution of
polyclonal antiserum to TRAMAL
(trans-(+-)-2-[(dimethylamino)methyl]-1-3metoxyphenyl-
)cyclohexanol hydrochloride) were given twice in the course of the
first hour as monotherapy. The arrest of the pain syndrome was
virtually achieved. Conventional disintoxication therapy was
prescribed.
[0093] B. Potentiated antibodies to BUTORPHANOL (MORADOL)
(17-cyclobuthylmethyl) morphinan-3,14-diol).
[0094] Patient R., aged 24, was admitted to a narcological
in-patient unit with an opiate withdrawal syndrome; the patient had
been taking various opiates for long time (6 months). The oral
intake of 30 ml of a C200 homeopathized solution of monoclonal
antibodies to MORADOL 3 times a day lessened the intensity of the
pain syndrome and the attraction to drugs.
[0095] C. Potentiated antibodies to PROMEDOL.
[0096] Patient S., aged 24, whose diagnosis was "heroin drug
addiction, remission of a 7 months' duration" applied for medical
advice complaining of pain in her right temporomandibular joint. No
organic lesions were found after examination. A D24 dilution of
potentiated antiserum to promedol,
(1,2,5-trimethyl-4-phenyl-4-piperidinol propanoate) was prescribed.
After a single dose of the preparation the pain disappeared with
background transitory manifestations of the so-called dry
abstinence. When questioned, the patient reported the easing of her
attraction to heroin that had increased 10 days earlier.
[0097] D. Potentiated antibodies to MORPHINE
(5.alpha.,6.alpha.)-7,8-dideh-
ydro-4,5-epoxy-17-methylmorphinan-3,6-diol.
[0098] Patient Z., aged 29, underwent appendectomy. In order to
control the postoperative pain he received a single 30 ml oral dose
of a C30 solution of potentiated antiserum to MORPHINE at bedtime.
The patient went to sleep. When questioned, he reported no feeling
of euphoria upon the intake of the preparation.
[0099] E. Potentiated antibodies to PHENTANYL
(N-Phenyl-N-[1-(2-phenylethy- l)-4-piperidinyl]propanamide).
[0100] Patient T., aged 68, complained upon admittance of pain in
her spine. She had a history of metastases of stomach cancer into
the vertebral bodies and of a long-time intake of narcotic
analgesics. A slow intravenous infusion of 2 ml of a D12 solution
of potentiated antibodies to PHENTANYL twice a day was prescribed.
After 4 days of the treatment the patient reported that the pain
syndrome subsided.
EXAMPLE 18
Potentiated Antibodies to Anticholinesterase Drugs
[0101] A. Potentiated antibodies to PHYSOSTIGMINE
((3aS-cis)-1,2,3a,8,8a-h-
exahydro-1,3a,8-trimethylpyrrolo[2,3-b]indole-5-ol
methylcarbamate).
[0102] Patient F., aged 63, was under medical observation after a
stroke. Objective findings: the muscular tension in the left arm
was lowered. The intranasal administration of 0.5 ml of a C50
solution of potentiated monoclonal antibodies to PHYSOSTIGMINE 3
times a day was prescribed within the framework of combined
therapy. After 3 weeks of the treatment normalization of the
muscular tension and reflexes was observed.
[0103] B. Potentiated antibodies to PROSERINE (3-[[dimethylamino)
carbonyl]-oxy]-N,N,N-trimethylbenzolaminium bromide).
[0104] Patient Ch., aged 60, after appendectomy suffered from the
onset of intestinal paresis in the postoperative period. The oral
intake of a C200 dilution of the antiserum to PROSERINE in a dose
of 1 tablet 3 times a day was prescribed. After 4 days of the
treatment the patient's gastrointestinal tract motility was back to
normal.
EXAMPLE 19
Potentiated Antibodies to Anti-glaucoma Drugs
[0105] Patient Ya., aged 70, had had a long-time history of
glaucoma. The patient had been taking ACETAZOLAMIDE (5-day courses
of 250 mg every 6 hours) to good effect. The preparation's
mechanism of action involves carbonic anhydrase blocking; on a
prolonged use its efficacy is reduced due to compensatory
mechanisms. Therefore, it was found necessary to discontinue the
use of the preparation from time to time. During these
interruptions of the treatment the attacks of glaucoma became more
frequent but the patient did not tolerate any other anti-glaucoma
drugs. The prescription of a C6 dilution of potentiated antibodies
to ACETAZOLAMIDE in a dose of 1 tablet a day resulted in the
restoration of the patient's sensitivity to the preparation; his
intraocular pressure did not go beyond the upper bound of normal;
the frequency of attacks of glaucoma was markedly reduced.
ACETAZOLAMIDE intake was discontinued. The term of follow-up was 4
months.
EXAMPLE 20
Potentiated Antibodies to Drugs Used for Migraine
[0106] A. Antibodies to DIHYDROERGOTAMINE
[0107] Patient N., aged 41, complained of cramping pain in the left
part of her head. The diagnosis of migraine was established; the
intranasal administration of a C200 dilution of potentiated
monoclonal antibodies to DIHYDROERGOTAMINE (5.alpha.,
10.alpha.)-9,10-dihydro-12-hydroxy-2-methyl--
5-(phenylmethyl)ergotamine-3,6,18-trione mesilate) 4 times a day
was prescribed. At her next visit to the physician 7 days later the
patient reported the lessening of both frequency and intensity of
pain. It was recommended to continue the course of treatment.
[0108] B. Antibodies to SUMATRIPTANE
(3-[2-(dimethylamino)ethyl-]-N-methyl-
indole-5-methanesulfonamide).
[0109] Patient K., aged 42, addressed herself to an out-patient
clinic complaining of attacks of headache localized in the left
part of her head and accompanied with nausea.
[0110] The prescription was to take orally 1 ml of a D24 solution
of potentiated monoclonal antibodies to SUMATRIPTANE at the time of
the attack of headache together with conventional analgesics. At
her next visit to the physician the patient reported the
disappearance of nausea and the lessening of the intensity of
pain.
EXAMPLE 21
Potentiated Antibodies to Local Anesthetics
[0111] A. Antibodies to LIDOCAINE
((2-diethylamino)-N-(2,6-dimethylphenyl) acetamide).
[0112] Patient R. aged 32, complained of heart palpitation. The
diagnosis of ventricular tachyarrhythmia was established on
examination. The recommendation was to take orally 1 tablet of a
C12 dilution of potentiated antibodies to LIDOCAINE every hour
during the attack. Using this drug, the patient reported
normalization of the heart rhythm.
EXAMPLE 22
Potentiated Antibodies to Non-steroid Antiinflammatory Drugs
[0113] A. Potentiated antibodies to DICLOFENAC
(2-[(2,6-dichlorophenyl) amino]benzeneacetic acid).
[0114] Patient M., aged 52, complained of pain in his knees. The
diagnosis of arthritis in the phase of exacerbation was established
on examination. The prescription was: compresses with a C6
homeopathic solution of antibodies to DICLOFENAC. After four
procedures the lessening of hyperemia and soreness of the joints
was noticed.
[0115] B. Potentiated antibodies to INDOMETHACINE.
[0116] Patient D., aged 48, complained of pain in the epigastric
area. He presented a long-time (1.5 month) history of the intake of
INDOMETHACINE
(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid).
Gastroscopy revealed erosive gastritis. The homeopathized solution
of an antiserum to indomethacine (a C30 potency) in the form of 1
tablet 3 times a day was prescribed. At a new examination 7 days
later the patient noted that the pain had disappeared.
[0117] C. POTENTIATED ANTIBODIES to CYCLOOXYGENASE.
[0118] Patient F., aged 49, had been suffering from rheumatoid
polyarthritis for 12 years. The use of NSAIDs of all groups
including MOVALIS (a preparation with a relatively selective effect
upon cyclooxygenase-2) was extremely problematic due to concomitant
hyperacidic gastritis. With the background treatment with a D12
dilution of a potentiated form of antibodies to cyclooxygenase-1 in
a oral dose of 1 tablet 2 times a day the patient tolerated MOVALIS
well. The pain in his joints subsided and the joint motility
regained. The endoscopic examination showed the remission of
hyperacidic gastritis.
[0119] D. POTENTIATED ANTIBODIES TO IBUPROFEN
(.alpha.-methyl-4-(2-methylp- ropyl) benzeneacetic acid).
[0120] Patient L., aged 56, complained of pain and limited motility
of her ankle joint. The oral intake of IBUPROFEN in combination
with the intranasal administration of 0.5 ml of a C12 dilution of
potentiated antibodies to .alpha.-methyl-4-(2-methylpropyl)
benzolacetic acid twice a day was prescribed. Five days later the
normalization of joint motility and the absence of pain were noted.
Ibuprofen was discontinued. The patient started receiving
potentiated antibodies as monotherapy. No inflammatory symptoms or
pain in her joints were found.
[0121] POTENTIATED ANTIBODIES TO ASPIRIN (2-(acetyloxy)benzoic
acid).
[0122] E. Patient T., aged 48, complained of headaches. The
examination revealed a temperature rise to 37.1.degree. C. A C30
preparation of potentiated antibodies to ASPIRIN in a dose of 1
tablet 4 times a day was recommended. Twenty-four hours later her
body temperature was back to normal and the headache subsided
completely.
[0123] F. Patient T., aged 48, with an established diagnosis of
ischemic heart disease developed instable angina attacks at minimal
physical strain. ACETYLSALICYLIC ACID (325 mg once a day) was among
the preparations the patient regularly took within the framework of
combined therapy. The patient complained of stomach discomfort; a
laboratory examination revealed the growth of the blood coagulation
time from 5 to 12 minutes. The prescription was: 1 ml of a C12
dilution of potentiated antibodies to ASPIRIN in the form of
intramuscular injections once a day. The stomach discomfort
disappeared and the blood coagulation time shortened to 8
minutes.
[0124] G. POTENTIATED ANTIBODIES to PARACETAMOL
(N-(4-hydroxyphenyl) acetamide.
[0125] Patient N., aged 11, was admitted to the hospital with an
acute respiratory tract infection. The examination revealed a
temperature rise to 38.2.degree. C. and rhinitis. In addition to
halazolin, the patient started receiving orally 10 ml of an aqueous
solution of potentiated antibodies to PARACETAMOL 4 times a day.
Twelve hours later his body temperature was back to normal and
rhinitis subsided.
EXAMPLE 23
Potentiated Antibodies to Pharmaceutical Agents Influencing the
Function of Respiratory Organs
[0126] A. POTENTIATED ANTIBODIES to PHENOTEROL
(1-(3,5-dioxyphenyl)-2-(par-
a-oxy-.alpha.-methyl-phenetylamino)-ethanol).
[0127] Patient K., aged 22, suffering from asthmatic bronchitis
used PHENOTEROL (berotec) in an aerosol form as his main
therapeutic agent. The patient stated the reliability and
efficiency of the preparation but complained of hand tremor and
heart palpitations associated with the medication. The use of a C30
dilution of potentiated antibodies to phenoterol in a dose of 1
tablet 2 times a day improved the patient's tolerance for the
preparation without affecting its efficacy. Gradually the patient
was switched to the potentiated preparation as monotherapy. No
asthmatic episodes were registered within 5 weeks of
observation.
[0128] POTENTIATED ANTIBODIES to ATROVENT.
[0129] B. Patient A., aged 26, suffered from polyvalent allergy
including intolerance to soybeans and peanuts. He had been
successfully receiving ATROVENT (in the form of an inhalation
solution) for frequent attacks of bronchial asthma. After a single
attempt to use ATROVENT in the form of an inhalation aerosol the
patient developed a severe anaphylactic reaction. The latter was
arrested by means of three intranasal administrations of 0.5 ml of
a D24 dilution of antibodies to atrovent with 20-minutes'
intervals. Later on the patient started receiving 1 tablet a day of
a D12 dilution of antibodies to atrovent every morning as
monotherapy. He was feeling well and had no attacks of bronchial
asthma in the course of three months.
[0130] C. Patient A., aged 45, had been taking THEOPHYLLINE for a
long time for the attacks of bronchial asthma until he noted the
loss of efficiency of the preparation. The oral intake of a C30
dilution of a potentiated solution of antibodies to THEOPHYLLINE
(1,3-dimethylxanthine) in a dose of 1 tablet 2 times a day enhanced
the efficacy of the therapy, which allowed the dose of theophylline
to be reduced.
[0131] D. Patient D., aged 36, had been suffering from bronchial
asthma since the age of 19. As his attacks occurred at night, he
split his daily dose of 600 mg of THEOPECK into 2/3 in the evening
and 1/3 in the morning. The patient complained of excessive
irritability and the worsening of sleep. An attempt to reduce the
dose of the preparation did not result in better sleep but
nocturnal asthmatic fits became more frequent. Once the treatment
with a C30 dilution of homeopathized antibodies to theophylline in
a dose of 1 tablet 2 times a day had been started, the patient's
sleep returned to normal within 3 weeks. The dose of theophylline
was reduced to 300 mg, the asthmatic fits became rare.
[0132] E. POTENTIATED ANTIBODIES to MENTHOL
(2-isopropyl-5-methylcyclohexa- nol-1).
[0133] Patient Ch., aged 39, complained of cough and dryness in his
throat. The recommendation was to take a tablet of potentiated
antibodies to MENTHOL (a C12 dilution) at the onset of a coughing
fit. At the next visit the patient reported the efficiency of the
preparation for controlling the cough. It was recommended to
continue the course of treatment.
[0134] Potentiated antibodies to adrenomimetic drugs
[0135] F. Potentiated antibodies to NAPHTHIZINE, (NAPHAZOLINE)
(4,5-dihydro-2-(1-naphthalinemethyl)-1H-imidazole).
[0136] Patient V., aged 49, complained of tachycardia after
administration of naphthizine for rhinitis. Naphtizine was replaced
by a homeopathic solution (a C6 dilution) of monoclonal antibodies
to 4,5-dihydro-2-(1-naphthalinemethyl)-1H-imidazole in a dose of 1
tablet 3 times a day. The patient reported normalization of his
cardiac rhythm, which made it possible to continue taking the
preparation. Twenty-four hours after the beginning of the treatment
rhinorrhea virtually disappeared.
[0137] G. Potentiated antibodies to SALBUTAMOL
(.alpha.1-[[(1,1-dimethylet-
hyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol).
[0138] Patient I., aged 54, complained of hard breathing fits. The
intranasal instillations of a C50 homeopathic solution of
antibodies to SALBUTAMOL in the form of 5 drops of an aqueous
solution 3 times a day were prescribed. The use of the preparation
made it possible to shorten the duration of hard breathing
fits.
EXAMPLE 24
Potentiated Antibodies to Histamine and Antihistamine Drugs
[0139] A. Potentiated antibodies to CROMOLYN
(5,5-[(2-hydroxy-1,3-propaned-
iyl)-bis-(oxy)]-bis-[4-oxo-4H-1-benzopyrane-2-carboxylic acid).
[0140] Patient M., aged 57, had been suffering from seasonal
pollinosis. The prescription of 1 ml of a C30 dilution of
potentiated antibodies to CROMOLYN in the form of nasal drops 2
times a day made it possible to control the symptoms of
rhinitis.
[0141] B. Potentiated antibodies to ZADITEN (KETOTIFEN)
(4,9-dihydro-4-(1-methyl-4-piperidinylidene-10H-benzo[4,5]cyclohepta[1,2--
b]-thiophen-10-one hydrofumarate).
[0142] Patient M., aged 29, a software programmer by profession has
been suffering from pollinosis with symptoms of
kerato-conjunctivitis during spring and summer. He used to control
exacerbations of his condition with 1 mg of ZADITEN (1 tablet) 2
times a day. The positive therapeutic effect of ZADITEN intake was
accompanied by a depressed intensity of emotional and physical
reactions, somnolence and listlessness. The administration of a C30
dilution of potentiated antibodies to ZADITEN in a dose of 1 tablet
2 times a day resulted in the elimination of ZADITEN's side
effects. The ZADITEN intake was discontinued; the patient continued
to receive the potentiated preparation as monotherapy. No
manifestations of hay fever were noted afterwards.
[0143] C. Potentiated antibodies to TAVEGYL
(1-methyl-2[2-(.alpha.-methyl--
para-chlorbenzhydryl-oxy)-ethyl]-pyrrolidine).
[0144] Patient Ch., aged 35, used to take TAVEGYL to good effect
for chronic urticaria. The parenteral administration of TAVEGYL (in
a dose of 2 ml intramuscularly) in the case of the next
exacerbation accompanied by a pronounced allergic skin syndrome and
a high eosinophile count (18%) in the peripheral blood resulted in
a rapid clinical and laboratory improvement (eosinophile count
going down to 7%); however, headache, nausea, and mouth dryness
were noted. The administration of a C12 dilution of potentiated
polyclonal antibodies to TAVEGYL in a dose of 1 tablet 2 times a
day resulted in the elimination of the side effects of TAVEGIL use.
Further on, the patient has been receiving TAVEGIL in combination
with potentiated antibodies to TAVEGIL; a month later she was put
on a maintaining dose of antibodies (once in three days) as
monotherapy.
[0145] D. Patient S., aged 48, was admitted to the pulmonology unit
for pneumonia. The patient had an anaphylactic shock in response to
the intravenous injection of calcium chloride. The intramuscular
injection of 1 ml of C50 dilution of potentiated antibodies to
HISTAMINE made it possible to arrest the symptoms of shock within 5
minutes.
[0146] E. POTENTIATED ANTIBODIES to KETOTIFEN
(4,9-dihydro-4-(1-methyl-4-p-
iperidinylidene)-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
hydrofumarate).
[0147] Patient D., aged 12, was hospitalized because of his
complaint of heavy breathing during the season of poplar
blossoming. The oral intake of 10 ml of a C24 dilution of
homeopathic solution of antiserum to KETOTIFEN 3 times a day
restored the patient's respiratory function to the normal
level.
[0148] Potentiated antibodies to inhibitors of H1-histamine
receptors.
[0149] F. Potentiated antibodies to LORATIDINE (CLARITINE) (ethyl
ester of
4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]cyclohepta[1,2-b]pyridin-1-ylidene-
)-1-piperidine carboxylic acid).
[0150] Patient K., aged 45, complained of an itching sensation in
her nasopharynx after working with paintwork materials. After the
administration of a C200 dilution of potentiated monoclonal
antibodies to LORATIDINE (in a dose of 1 tablet 2 times a day)
itching subsided. It was concluded that the preparation had proved
its efficiency.
[0151] Potentiated antibodies to TAVEGYL (CLEMASTINE)
([R-(R*,R*)]-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrro-
lidine fumarate or
1-methyl-2[2-(.alpha.-methyl-para-chlorbenzhydryl-oxy)--
ethyl]-pyrrolidine fumarate).
[0152] Patient P., aged 34, complained of somnolence after the
intake of TAVEGIL for the itching of her elbows. The oral intake of
a D6 dilution of potentiated antibodies to
[R-(R*,R*)]-2-[2-[1-(4-chlorophenyl)-1-pheny-
lethoxy]ethyl]-1-methylpyrrolidine fumarate in a dose of 1 tablet 2
times a day was recommended. At her next visit to the physician the
patient reported that her drowsiness had subsided and her mood
improved. She was put on the potentiated preparation as
monotherapy. At her visit to the physician 2 months later the
patient reported that her itching had virtually disappeared.
EXAMPLE 25
Potentiated Antibodies to Medications Used for Treatment of Erosive
Lesions of Gastrointestinal Tract
[0153] POTENTIATED ANTIBODIES to inhibitors of H2-histamine
receptors.
[0154] A. POTENTIATED ANTIBODIES to RANITIDINE
(N-[2]-[[[5-[(Dimethylamino- )
methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2-nitro-1,1-ethendiamine).
[0155] Patient N., aged 56, complained of epigastric pain. The
prescription was: 1 tablet of a C12 dilution of a potentiated
polyclonal antiserum to RANITIDINE
(N-[2]-[[[5-(dimethylamino)methyl]-2-furanyl]-met-
hyl]-thio]-ethyl]-N-methyl-2-nitro-1,1-ethendiamine) to be taken
after meals. After 3 days of the treatment the pain
disappeared.
[0156] B. Potentiated antibodies to FAMOTIDINE
(3-[[[2-[(aminoiminomethyl)-
-amino]-4-thiazolyl]-methyl]-thio]-N-(aminosulfonyl)-propaneimidamide).
[0157] Patient G., aged 45, complained of nausea after meals.
Gastroscopy revealed gastritis in an exacerbation phase. The
recommendations involved diet and the oral intake of 10 ml of a C30
solution of potentiated polyclonal antibodies to FAMOTIDINE before
meals. After 5 days of the treatment the patient's general
condition and the gastroscopic pattern of his gastric mucosa were
back to normal.
[0158] Potentiated antibodies to proton pump inhibitors
[0159] C. Potentiated antibodies to OMEPRAZOLE
(5-metoxy-2-[[(4-metoxy-3,5- -dimethyl-2-pyridinyl)methyl
sulfonyl)-1H-benzimidazole).
[0160] Patient U., aged 33, felt a pronounced pain in the pit of
the stomach from time to time. Gastroscopy revealed erosive
gastritis. After the administration of a C12 homeopathic dilution
of the preparation of polyclonal antibodies to OMEPRAZOLE in a dose
of 1 tablet 3 times a day along with a diet the gastric mucosa was
back to normal 6 days later and both frequency and intensity of
pain diminished.
[0161] D. Patient A., aged 44, with an established diagnosis of
ulcerative disease of stomach and duodenum in the phase of
exacerbation had been taking OMEZ (20 mg daily, a proton pump
inhibitor) for 4 weeks. Against the background of an improvement of
the course of the disease the patient complained of dizziness and
headache. The treatment with a D12 dilution of potentiated
antibodies to OMEZ in a dose of 1 tablet 3 times a day resulted in
the elimination of side effects on the part of the central nervous
system and in the improvement of the patient's general condition
within 3 days. Later on, the remission was maintained solely by the
intake of potentiated antibodies to OMEZ.
[0162] Potentiated antibodies to M-cholinolytic drugs.
[0163] E. Potentiated antibodies to PIRENZEPINE (GASRTOZEPINE)
(5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]-6H-pyrido[2,3-b][1,4]be-
nzodiazepine-6-one).
[0164] Patient P., aged 57, complained of tremor and pain in the
pit of his stomach after meals. Gastroscopy revealed no organic
lesions of stomach mucosa. The oral intake of a D8 homeopathic
solution of antiserum to GASRTOZEPINE in a dose of 1 tablet before
meals was recommended. A new examination 10 days later showed an
improvement of the patient's mood; no epigastric pain was noted. It
was concluded that the preparation was efficient.
[0165] F. Potentiated antibodies to ATROPINE
(8-methyl-8-azabicyclo[3.2.1.- ]oct-3-yl ester of
endo-(+-)-.alpha.-(hydroxymethyl)benzolacetic acid).
[0166] Patient M., aged 41, suffered of cramps in his right
subcostal area 2 hours after meals rich in fat. The prescription
was: a diet and the oral intake of a C200 aqueous solution of
potentiated polyclonal antibodies to ATROPINE in a dose of 10 ml
(after meals). The pain syndrome subsided 2 days later. It was
recommended to continue the course of treatment.
[0167] G. Patient F., aged 42, suffered from sinus bradycardia; his
pulse rate was 48 beats/min. He had been taking the BELLADONNA
EXTRACT in tablets; the positive therapeutic effect of the extract
(the pulse rate increased to 64 beats/min) was accompanied by
general weakness and dryness of skin and mucosae. (ATROPINE, the
active principle of the extract, is the tropinic ester of
d,l-tropic acid; the L isomer is active whereas the D isomer
manifests low activity). The recommendation was to take alternately
potentiated antibodies (a C15 dilution) to both isomers. The
patient's pulse rate stabilized at 64 beats/min; no cholinolytic
side effects were observed.
[0168] H. Antibodies to NO-SPA (drotaverine)
([(3,4-diethoxyphenyl)methyle-
ne]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline).
[0169] Patient L., aged 38, complained of epigastric pain and
belching. He examination revealed no organic lesions. The
prescription was: the oral intake (before meals) of an aqueous
solution (a C6 dilution) of monoclonal antibodies to NO-SPA
(drotaverine) in a dose of 15 ml. After 2 days of the treatment the
patient stated the lessening of dyspeptic manifestations.
EXAMPLE 26
Potentiated Antibodies to Antiemetic Drugs
[0170] A. Potentiated antibodies to DOMPERIDONE (MOTILIUM)
(5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piper-
idinyl]-1,3-dihydro-2H-benzimidazol-2-one).
[0171] Patient N., aged 71, had been treated with levodopa for
parkinsonism and had to stop the therapy because of nausea and
vomiting. The oral intake of levodopa in combination with 30 ml of
a C30 dilution of an aqueous solution of potentiated monoclonal
antibodies to MOTILIUM was prescribed, which made it possible to
eliminate vomiting and continue antiparkinsonic therapy.
[0172] B. Patient Zh., aged 64, developed nausea and vomiting in
response to radio- and chemotherapy he had been getting for
peripheral lung cancer. The prescription of MOTILIUM controlled
symptoms of dyspepsia but the patient developed weakness,
drowsiness, and intestinal cramps. MOTILIUM was discontinued and a
C6 dilution of potentiated antibodies to MOTILIUM was administered
in a dose of 1 ml intramuscularly 2 times a day, which resulted in
the elimination of neurotoxic and spastic reactions. The treatment
was continued with a positive clinical effect.
[0173] C. Patient Yu., aged 55, suffered from chronic gastritis and
esophagitis. He had been taking MOTILIUM (the active principle is
DOMPERIDONE, an antagonist of dopamine receptors) for 3 months in a
dose of 10 mg 15-20 minutes before meals on his own initiative
under the influence of commercial advertising. He sought for
medical advice because of gynecomastia he had noticed. Motilium was
discontinued and a C1000 dilution of potentiated antiidiopathic
antibodies to DOMPERIDONE was prescribed for 2 months in a dose of
1 tablet a day. The symptoms of gynecomastia disappeared and
dyspeptic problems never resumed.
[0174] D. Potentiated antibodies to METOCLOPRAMIDE (REGLAN,
CERUCAL)
(4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-metoxybenzamide).
[0175] Patient D., aged 38, complained of nausea and belching after
meals. A course of treatment with an oral preparation containing a
C30 dilution of potentiated antibodies to METOCLOPRAMIDE (REGLAN,
CERUCAL) in a dose of 2 tablets before meals was prescribed. Four
days later the patient reported the disappearance of nausea. A
conclusion about the efficiency of the preparation was drawn.
EXAMPLE 27
Potentiated Antibodies to Antitussive Drugs
[0176] A. Potentiated antibodies to CODEINE
((5.alpha.,6.alpha.)-7,8-dideh-
ydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol).
[0177] Patient B., aged 47, complained of fits of dry cough. The
diagnosis was: chronic bronchitis; the intranasal administration of
a C200 dilution of an aqueous solution of potentiated monoclonal
antibodies to CODEINE in a dose of 5 drops during a fit was
recommended. Twenty-four hours after the beginning of the treatment
the elimination of cough was registered.
[0178] B. Potentiated antibodies to LIBEXIN (PRENOXDIAZINE)
(1-[2-[3-(2,2-diphenylethyl)-1,2,4-oxydiazol-5-yl]ethyl]piperidine).
[0179] Patient T., aged 41, had been taking LIBEXIN tablets for her
cough. She complained of dryness in her mouth and throat. LIBEXIN
was discontinued. The suggestion was to take orally a C50 dilution
of a potentiated antiserum to
1-[2-[3-(2,2-diphenylethyl)-1,2,4-oxydiazol-5-yl- ]ethyl]piperidine
in a dose of 1 tablet 3 times a day. The administration of the
homeopathic preparation eliminated the undesired symptoms within 2
hours. The examination two days later showed a satisfactory general
condition of the patient and the absence of cough.
EXAMPLE 28
Potentiated Antibodies to Various Groups of Antihypertensive
Drugs
[0180] Potentiated antibodies to sympatholythics.
[0181] A. Potentiated antibodies to RESERPINE
[0182] Patient B., aged 36, had been taking a course of treatment
with ADELPHAN for arterial hypertension. After 3 weeks of the
treatment she started complaining of dizziness. The examination
revealed that her blood pressure had dropped to 105/60 mm Hg.
ADELPHAN was discontinued. The oral intake of a C12 dilution of
potentiated antiserum to RESERPINE in a dose of 1 tablet 2 times a
day was prescribed. Two days later her dizziness subsided and the
blood pressure rose to 115/70 mm Hg.
[0183] B. Patient P., aged 72, suffered from hypertensive disease,
Stage IIb. She had been taking RAUNATINE (1 tablet 2 times a day)
for a long time to good effect. The patient complained of dizziness
and stuffiness in her nose not associated with a common cold. A C50
dilution of potentiated antibodies to RESERPINE was prescribed;
this agent lessened her dizziness and completely eliminated
stuffiness in her nose. Later on, she had been taking the
preparation for 3 months in a dose of 1 tablet 2 times a day. Her
blood pressure stabilized at a level of 140/90 mm Hg.
[0184] Potentiated antibodies to .alpha.-adrenolytic drugs.
[0185] C. Potentiated antibodies to PRAZOSIN (MINIPRESS)
(1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-(2-furanylcarbonyl)piperazine).
[0186] Patient Ch., aged 53, complained of headaches after the
intake of PRAZOSIN for hypertensive disease. The prescription of a
C30 dilution of a potentiated antiserum to
(1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-(2-f- uranylcarbonyl)
piperazine) in a dose of 1 tablet together with the intake of the
PRAZOSIN resulted in the lowering of the patient's blood pressure.
Later on, he started the administration of the antibodies as
monotherapy; the blood pressure did not rise above his optimal
level of 150/90 mm Hg.
[0187] D. Patient I., aged 64, with an established diagnosis of
arterial atherosclerosis (predominantly of the vessels of his lower
extremities) and hypertensive disease, Stage IIb, had been taking
PRAZOSIN in a dose of 8 mg a day (16 tablets). The patient
complained of nausea and constant drowsiness. An attempt to reduce
the dose on his own initiative resulted in a rise of the blood
pressure and reappearance of the pain in his legs. The
administration of a C12 dilution of potentiated antibodies to
PRAZOSIN in a dose of 1 tablet 3 times a day made it possible to
eliminate the undesirable manifestations and to reduce the dose of
PRAZOSIN to 10 mg a day. Two months later the patient switched to
the maintaining dose of 1 tablet a day of a C50 dilution of
potentiated antibodies to PRAZOSIN.
[0188] E. Patient Shch., aged 69, has been receiving 1 tablet of
OMNIC (400 mg after breakfast) for benign hyperplasia of the
prostate. The patient developed symptoms of orthostatic
hypotension. The treatment with a C30 dilution of potentiated
antibodies to OMNIC in a dose of 1 tablet 3 times a day was begun.
Orthostatic symptoms disappeared 2 days later whereas the
therapeutic effect of the preparation was preserved: the patient
felt better, the volume of the residual urine diminished and the
frequency of urinations reduced.
[0189] Potentiated antibodies to CLOFELINE
(2,6-dichloro-N-2-imidazolidiny- lidenbenzamine).
[0190] F. Patient E., aged 58, complained of drowsiness after the
administration of CLOFELINE she had been taking for hypertensive
disease. The recommendation was to combine the intake of CLOFELINE
and a C12 solution of monoclonal antibodies to
2,6-dichloro-N-2-imidazolidinylidenb- enzamine in a dose of 1
tablet 3 times a day. After two days of the treatment the patient
stated the improvement of her mood and an enhanced motor activity.
CLOFELINE was gradually discontinued. Now the patient receives only
the potentiated drug; he arterial blood is stable.
[0191] G. Patient Yu., aged 59, had a 10-years' history of
essential hypertension. A regular intake of CLOFELINE in a dose of
0.6 mg a day produced a favorable effect on the course of his
illness. He sought for medical advice at his district outpatient
clinic because of dryness in the mouth. Several weeks of the
administration of a C200 dilution of potentiated antibodies to
CLOFELINE in a dose of 15 drops of an aqueous solution 4 times a
day resulted in the elimination of the undesirable manifestations.
The patient was switched to the potentiated preparation alone as
the maintaining therapy.
[0192] Potentiated antibodies to isomers of NEBILET.
[0193] H. Patient R., aged 63, with an established diagnosis of
hypertensive disease, Stage IIa, was on NEBILET treatment (the drug
contains two isomers; both are biologically active but their
metabolization rate varies in different people). The patient
complained of nightmares, which had not been experienced before the
NEBILET administration. Pharmacokinetic studies showed that the
patient belonged to the group with a slow type of metabolism (high
difference in the concentrations of L- and D-enantiomers in the
plasma). The administration of a D24 dilution of potentiated
antibodies to L-isomer in a dose of 1 tablet 3 times a day resulted
in the normalization of sleep along with the conservation of a good
hypotensive effect.
[0194] I. Patient P., aged 67, has been taking LABETALOL (400 mg a
day) for hypertensive disease. The patient complained of heavy
breathing. A C15 dilution of potentiated antibodies to RR-isomer in
an oral dose of 10 ml two times a day was prescribed. After two
days of treatment the patient's condition improved and functional
tests showed the improvement of bronchial conduction.
[0195] Potentiated antibodies to inactive isomers of LABETALOL.
[0196] J. Patient A., aged 57, with an established diagnosis of
hypertensive disease and ischemic heart disease took LABETALOL and
complains of heavy breathing and dizziness. The prescription was: a
mixture of a C30 dilution of potentiated antibodies to inactive
isomers in a dose of 1 sachet of powder a day. The patient's
condition improved and the dose of the drug was reduced from 400 mg
to 50 mg a day.
[0197] K. Patient Ya., aged 61, with an established diagnosis of
hypertensive disease and ischemic heart disease took APRESSIN
(HYDRALAZINE) (1-hydrazinophthalazine hydrochloride) 250 mg a day
in 4 doses. She complained of headaches, hot flashes, and nausea.
An attempt to reduce the dose did not result in the desired effect.
The recommendation was start taking a D8 dilution of potentiated
monoclonal antibodies to the hydrazine group of the APRESSIN
molecule; this group is capable of inhibiting the inactivation of
endogenous vasodilating factors (NO in particular). After two days
of treatment with this preparation in a dose of 1 tablet before
meals the patient noticed the improvement of her condition. The
treatment with APRESSIN was continued; its dose was reduced without
any attenuation of its pronounced therapeutic effect and two months
later APRESSIN was discontinued. The patient was put on monotherapy
with the antibodies.
[0198] Potentiated antibodies to calcium channel blockers.
[0199] Potentiated antibodies to NORVASK (AMPLODIPINE)
(3-ethyl-5-methyl ester of
2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methy-
l-3,5-pyridine dicarboxylic acid).
[0200] B. Patient Ch., aged 59, took NORVASK for hypertensive
disease. He complained of headache after the intake of the
preparation. The prescription was: the intranasal administration of
1 ml of a C1000 dilution of potentiated antiserum to
3-ethyl-5-methyl ester of
2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyr-
idine dicarboxylic acid once a day in the form of 10 drops to be
taken 3 times a day. The next day his headache disappeared. The
patient kept taking the two medications together. Six months later
the patient was put on monotherapy with the potentiated
preparation.
[0201] Potentiated antibodies to the antagonists of ACE and of
angiotensin-2 receptors.
[0202] Potentiated antibodies to CAPTOPRIL
((S)-1-(3-mercapto-2-methyl-1-o- xopropyl)-L-proline).
[0203] M. Patient L., aged 40, complained of periodical headaches
and episodes of hypertension. The oral intake of a C50 homeopathic
solution of potentiated antibodies to CAPTOPRYL in a dose of 5 ml 2
times a day was recommended. Within 10 days of the treatment a
decrease in the frequency of headaches was noticed.
[0204] Potentiated antibodies to LOSARTAN (COZAAR)
(2-butyl-4-chloro-1-[[2-
-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol).
[0205] N. Patient G., aged 46, complained of tremor. He had a
history of LOSARTAN intake for his hypertensive disease. The
recommendation was to take a D24 dilution of potentiated antibodies
to 2-butyl-4-chloro-1-[[2-(-
1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol
in a dose of 1 tablet 2 times a day. After three days of the
treatment tremor disappeared. Later on, in order to keep his blood
pressure stable the patient received only potentiated
antibodies.
[0206] O. Patient E., aged 42, with an established diagnosis of
essential arterial hypertension had been taking MOXONIDINE in a
dose of 300 mg a day. The patient complains of dryness in his mouth
and drowsiness. The treatment with a C30 dilution of potentiated
antibodies to MOXONIDINE produced a positive effect. Later on, the
patient was put on preventive treatment with antibodies to
MOXONIDINE in a dose of 1 tablet a day.
[0207] P. Patient M., aged 58, with an established diagnosis of
essential arterial hypertension, Stage IIb had been taking
ENALAPRIL
(1-[N-[S]-1-carboxy-3-phenylpropyl]-L-alanyl]-L-proline-1'-ethyl
ester), an angiotensin-converting enzyme inhibitor) on her
physician's advice in a dose of 20 mg once a day. She complains of
cough and dyspepsia. The patient used to take medications for the
treatment of the intestinal microflora disorder on her own
initiative with no positive results. The bacteriological testing of
her intestinal microflora yielded no pathological findings.
ENALAPRIL was discontinued. The new therapy scheme included the
addition of a C200 dilution of potentiated antibodies to ENALAPRIL
in a dose of 1 tablet once a day. The patient's bowel function
normalized and the cough ceased.
[0208] Q. Patient Z., aged 47, with an established diagnosis of
hypertensive disease had been taking VALSARTAN in a dose of 80 mg a
day. She complained of incessant cough and pharyngitis. Neither
X-ray examination nor phthisiologist's and otolaryngologist's
consultations revealed any pathology. The administration of C30
potentiated antibodies to VALSARTAN in a dose of 1 tablet 2 times a
day eliminated the side effects of the preparation. After that the
dose of VALSARTAN was reduced first to 40 mg a day and later to 20
mg a day with a stable hypotensive effect.
[0209] Potentiated antibodies to DILTIAZEM.
[0210] R. Patient C., aged 54, with an established diagnosis of
hypertensive disease, ischemic heart disease, angina decubitus had
been taking DILTIAZEM in a dose of 40 mg 4 times a day with good
clinical effect. Rare attacks of angina: about once a week. After
1.5 month of treatment the patient noticed the slowing of the pulse
rate (from 72 to 48-52 beats/min); the ECG indicated the extension
of the P-Q interval from 0.12 to 0.20 s. The treatment with a D24
dilution of potentiated polyclonal antibodies to DILTIAZEM in a
dose of 1 tablet 3 times a day was prescribed. The patient's pulse
rate reached 60 beats/min, the P-Q interval shortened to 0.15 s,
without angina attacks becoming more frequent. The dosage of
DILTIAZEM was reduced to 20 mg 2 times a day.
[0211] Potentiated antibodies to spasmolytic drugs.
[0212] Potentiated antibodies to DIBAZOLE
(2-(phenylmethyl)-1H-benzimidazo- le).
[0213] S. Patient Z., aged 41, complained of headache and nausea.
The diagnosis of hypertensive disease was established and the oral
intake of a C12 homeopathic solution of polyclonal antibodies to
DIBAZOLE in a dose of 1 tablet 2 times a day was recommended. Ten
days later the patient reported feeling better and not suffering
from headaches.
EXAMPLE 29
Potentiated Antibodies to Substances Taking Part in Natural
Regulation of the Blood Pressure
[0214] A. Patient S., aged 46, had been sent to hospital within
several years because of hypertension crises. Once a crisis had
been arrested the patient was put on the maintaining therapy with
captopril. In order to enhance the hypotensive effect a C12
dilution of potentiated antibodies to RENIN in a dose of 1 tablet 2
times a day was added to the treatment. Combined therapy made it
possible for the first time in many years to lower the patient's
blood pressure to 140/100 mm Hg. The patient's condition is
satisfactory.
[0215] B. Patient H., aged 38, suffered from therapy-resistant
essential hypertension. The closest to optimal drug for the patient
was ENALAPRIL, which made it possible to stabilize the blood
pressure at 160/110 mm Hg. The treatment protocol with an added
intake of a D24 dilution of potentiated polyclonal antibodies to
ANGIOTENSIN-CONVERTING ENZYME (in a dose of 15 drops of alcohol
solution 3 times a day) made it possible to lower the patient's
systolic pressure to 120-130 mm Hg. The patient had not presented
any complaints for 2 months.
[0216] C. Patient D., aged 19, had been suffering from
therapy-resistant arterial hypertension for 6 months. The use of a
C12 dilution of potentiated antibodies to ANGIOTENSIN II in a dose
of 1 tablet 2 times a day made it possible to stabilize the
patient's condition: no complaints, the blood pressure reached
120/75 mm Hg.
EXAMPLE 30
Potentiated Antibodies to Diuretic Drugs
[0217] Potentiated antibodies to FUROSEMIDE
(5-(aminosulfonyl)-4-chloro-2-- [(2-furanylmethyl)]aminobenzoic
acid).
[0218] A. Patient D., aged 67, had been taking a course of
treatment with FUROSEMIDE for edemata caused by cardiac failure.
She complained of nausea and the lack of appetite. Furosemide was
discontinued. The recommendation was to start the oral intake of a
C30 aqueous solution of potentiated monoclonal antibodies to
5-(aminosulfonyl)-4-chloro-2-[(2-fur- anylmethyl)]aminobenzoic acid
2 times a day in a dose of 20 ml. A new examination 7 days later
revealed the improved appetite, the absence of nausea and
edemata.
[0219] Potentiated antibodies to HYPOTHIAZIDE
(6-chloro-3,4-dihydro-2H-1,2-
,4-benzothiadiazine-7-sulfonamide-1,1-dioxide).
[0220] B. Patient N., aged 64, with established diagnosis of
hypertensive disease had been taking HYPOTHIAZIDE. The patient
noticed a decrease in the efficacy of the preparation; hence,
HYPOTHIAZIDE was discontinued. The recommendation was to start the
oral intake of a C200 dilution of a potentiated antiserum to
hypothiazide in a dose of 1 tablet 3 times a day, which made it
possible to preserve the diuretic effect after hypothiazide had
been discontinued.
EXAMPLE 31
Potentiated Antibodies to Cardiotropic Drugs
[0221] Potentiated antibodies to nitrates.
[0222] Potentiated antibodies to
NITROSORBIDE(1,4,3,6-dianghydrido-D-gluci- tol dinitrate).
[0223] A. Patient Sh., aged 52, suffering from hypertensive disease
complained of headache after the first intake of NITROSORBIDE. In
addition to the conventional treatment, the oral intake of a C20
dilution of potentiated antiserum to NITROSORBIDE was prescribed in
a dose of 10 ml 3 times a day. Seven days later the patient
reported an improved tolerance to NITROSORBIDE and the lessening of
pain.
[0224] Potentiated antibodies to NITROGLYCEROL.
[0225] B. Patient U., aged 71, had been taking NITROSORBIDE (40 mg
a day, 4 tablets) for 5 weeks for ischemic heart disease and angina
of effort along with NITROGLYCEROL as needed (up to 8-10 tablets a
day). Within the last week the dose of NITROSORBIDE was increased
to 6 tablets, and that of NITROGLYCEROL, to 15-16 tablets as the
angina attacks grew more frequent. The prescription was to take a
C6 dilution of potentiated antibodies to NITROGLYCEROL in a dose of
1 tablet 2 times a day. After 5 days of treatment a marked
reduction in the frequency of attacks was achieved, which made it
possible to reduce the dose of NITROSORBIDE to 4 tablets and that
of NITROGLYCEROL to 1-2 tablets a day.
[0226] Potentiated antibodies to Cytochromes a+a3.
[0227] C. Patient G., aged 39, was admitted to hospital with the
diagnosis of hypertensive disease, ischemic heart disease, cardiac
failure due to myocardial infarction; he had been treated with
intravenous infusions of SODIUM NITROPRUSSIDE (sodium
nitrozylpentacyanoferrate) in a dose of 100 mg a day for 4 days. By
the 5.sup.th day the hypotensive effect of the preparation had
significantly decreased as sodium cyanide accumulating as a result
of SODIUM NITROPRUSSIDE metabolism played an important part in the
pharmacological effect of the preparation. (Cyanides act as
blockers of the mitochondria respiratory chain at the level of
Cytochrome a+a3). The administration of a C200 dilution of
potentiated polyclonal antibodies to CYTOCHROMES a+a3 in a dose of
1 tablet 3 times a day restored the efficacy of SODIUM
NITROPRUSSIDE.
[0228] Potentiated antibodies to .beta.-adrenoblockers.
[0229] Potentiated antibodies to ATENOLOL
(4-[2-hydroxy-3-[(1-methylethyl)
amino]propoxy]benzeneacetamide).
[0230] D. Patient E., aged 32, complained of episodes of
tachycardia caused by overfatigue. Electrocardiography revealed no
organic lesions. ATENOLOL was discontinued. The oral intake of a
C12 dilution of a potentiated antiserum to ATENOLOL was prescribed.
The intake of the preparation in a dose of 1 tablet 2 times a day
resulted in a decrease both in the intensity and duration of
episodes of tachycardia 5 days after the beginning of
treatment.
[0231] Potentiated antibodies to ANAPRILIN (PROPRANOLOL)
(1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol).
[0232] E. Patient I., aged 54, sought for medical advice for
periodic heavy breathing. She presented a history of a regular
intake of ANAPRILIN (PROPRANOLOL). The intranasal administration of
a C12 dilution of a potentiated solution of monoclonal antibodies
to 1-[(1-methylethyl)amino]- -3-(1-naphthalenyloxy)-2-propanol in a
dose of 0.5 ml 2 times a day was prescribed as monotherapy. A new
examination 7 days later showed an improvement of the respiratory
function. A conclusion about the efficacy of the homeopathic
preparation was drawn.
[0233] F. Patient A., aged 57, developed bradyarrhythmia with
Morgagni-Adams-Stokes attacks after myocardial infarction. To
prevent attacks she took ORCIPRENALINE (1/2 tablet 6 times a day)
and complained of nausea, dryness in her mouth, and the tremor of
her hands. The treatment with a D3 dilution of potentiated
monoclonal antibodies to ORCIPRENALINE (in a dose of 1 tablet 3
times a day) made it possible to eliminate the unpleasant
sensations; the attacks of arrhythmia stopped recurring.
[0234] Potentiated antibodies to cardiac glycosides.
[0235] Potentiated antibodies to DIGITOXIN
((3.beta.,5.beta.)-3-[(O-2,6-di-
desoxy-.beta.-D-ribo-hexopyranozyl-(1-4)-O-2,6-didesoxy-.beta.-D-ribo-hexo-
pyranozyl)-(1-4)-2,6-didesoxy-.beta.-D-ribo-hexapyranozyl)oxy]-14-hydroxyc-
ard-20(22)-enolide).
[0236] G. Patient B., aged 68, had been taking a course of
treatment with DIGITOXIN for cardiac failure complained of nausea
associated with the intake of the preparation. The additional
prescription was the oral intake of a C200 dilution of a
potentiated preparation of polyclonal antibodies to
(3.beta.,5.beta.)-3-[(O-2,6-didesoxy-.beta.-D-ribo-hexopyra-
nozyl-(1-4)-O-2,6-didesoxy-.beta.-D-ribo-hexopyranozyl)-(1-4)-2,6-didesoxy-
-.beta.-D-ribo-hexapyranozyl)oxy]-14-hydroxycard-20(22)-enolide in
a dose of 1 tablet 2 times a day. After two days of the treatment
the patient noticed the disappearance of nausea. The intake of the
homeopathic preparation made it possible to improve the patient's
tolerance of DIGITOXIN and to reduce gradually its dose to 1/4 of a
tablet 2 times a day.
[0237] H. Patient Ch., aged 31, with an established diagnosis of
chronic cardiac failure caused by rheumatic heart disease had been
taking the maintaining dose of DIGITOXIN 0.75 mg a day (3 tablets).
She suffered from permanent nausea and periodical vomiting. An
attempt to reduce the dose of DIGITOXIN resulted in the enhancement
of manifestations of cardiac failure, edema in the first place.
With DIGITOXIN discontinued, the patient started receiving a D6
dilution of potentiated antiidiotypic antibodies to DIGITOXIN (in a
dose of 1 tablet 3 times a day). Two weeks later the patient's
condition was satisfactory: the blood pressure became stable and no
manifestations of cardiac failure were observed
[0238] Potentiated antibodies to antiarrhythmic drugs.
[0239] Potentiated antibodies to DISOPYRAMIDE
(.alpha.-[2-[bis(1-methyleth-
yl)amino]ethyl]-.alpha.-phenyl-2-pyridine acetamide).
[0240] I. Patient S., aged 35, complained of restlessness and
tachycardia. The oral intake of a C200 dilution of potentiated
monoclonal antibodies to RYTHMILEN (DISOPYRAMIDE)
(.alpha.-[2-[bis(1-methylethyl)amino]ethyl]-.-
alpha.-phenyl-2-pyridine acetamide) in a dose of 1 tablet 2 times a
day was prescribed. At the new examination the patient presented no
complaints for tachycardia.
[0241] Potentiated antibodies to RHYTHMONORM.
[0242] J. Patient Zh., aged 45, has been taking RHYTHMONORM
(Propaphenone)
(2[2-hydroxy-3-(propylamino)propoxy]-3-phenyl-propiophenone), an
antiarrhythmic drug of the IC class) in a dose of 150 mg 3 times a
day for ventricular extrasystoles. The planned blood test revealed
leukopenia (3.8.times.10.sup.3/.mu.l) and thrombocytopenia
(170.times.10.sup.3/.mu.l- ). Rhythmonorm was discontinued. The
administration of a C50 dilution of potentiated antibodies to
PROPAPHENONE in a dose of 1 tablet in the morning within 10 days
resulted in the normalization of the patient's blood picture with
preserved antiarrhythmic effect.
[0243] Potentiated antibodies to SOTALOL
(N-[4-[1-hydroxy-2-[(1-methylethy- l) amino]ethyl]phenyl]methane
sulfonamide)
[0244] K. Patient D., aged 28, complained of night episodes of
pulse intermittence, mild pain in the left part of her thorax.
Electrocardiography revealed no organic lesions of the myocardium.
After the preceding therapy had been cancelled, the patient started
the oral intake of a C30 dilution of potentiated antibodies to
SOTALOL
(N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methane
sulfonamide) in a dose of 1 tablet at bedtime. During the following
10 days there were no attacks of arrhythmia or pain.
[0245] Potentiated antibodies to VERAPAMIL
(.alpha.-[3-[[2-(3,4-dimetoxyph- enyl)
ethyl]methylamino]propyl]-3,4-dimetoxy-.alpha.-(1-methylethyl)benzen-
eacetonitryl).
[0246] L. Patient K., aged 34, complained of headache, tachycardia,
and overfatigue. The examination revealed elevated blood pressure
(140/90). The recommendation was to take nasal drops of a C200
aqueous solution of potentiated antibodies to VERAPAMIL
(.alpha.-[3-[[2-(3,4-dimetoxyphenyl)
ethyl]methylamino]propyl]-3,4-dimetoxy-.alpha.-(1-methylethyl)benzeneacet-
onitryl) in a dose of 0.5 ml at bedtime. The patient reported
feeling better, his blood pressure dropped to the normal level
after two days of the treatment. It was recommended to continue the
course of treatment.
[0247] M. Patient Z., aged 55, with an established diagnosis of
ischemic heart disease, angina of effort, atrial extrasystoles, and
tachycardia (90 beats/min) had been taking 240 mg of ISOPTIN daily
in a dose of 1 tablet 3 times a day. The patient complained of
constipation not associated with the regimen faults or diet
changes. The intake of potentiated antibodies to ISOPTIN LM 50 in a
dose of 1 tablet 2 times a day resulted in the normalization of the
bowel function without interfering with the basic therapeutic
effect of ISOPTIN. Later on, the dose of ISOPTIN was gradually
reduced and finally ISOPTIN was discontinued. The patient's
condition remained satisfactory for two months against the
background of therapy with antibodies.
[0248] N. Patient D., aged 63, with the diagnosis of progressive
chronic cardiac failure was treated at the cardiology unit of a
clinical hospital (intravenous infusion of 30 mg of MILRINONE daily
in a dose of 10 ml 3 times a day). As the patient's myocardial
contractive capacity and hemodynamic indices were gradually
improving, there appeared complaints of heartache. ECG revealed
signs of myocardial ischemia. The treatment with a C12 dilution of
potentiated antibodies to MILRINONE in a dose of 1 tablet 3 times a
day was started. Heartache disappeared, the ECG pattern returned to
normal, and the treatment with MILRINONE was continued. Gradually
the preparation was discontinued and the patient was switched to
the treatment with antibodies alone in a dose of 1 tablet a day.
The patient's condition is satisfactory.
[0249] O. Patient S., aged 58, had been taking MILRINONE for 1.5
years for chronic cardiac failure. In the course of the period of
treatment the daily dose had to be increased from 10 to 30 mg
because of the developing resistance to the preparation. After the
prescription of a C30 dilution of potentiated antibodies to the
enzyme PHOSPHODIESTERASE in a dose of 1 sublingual tablet once a
day to be taken in the morning the patient's condition markedly
improved: the ECG signs of myocardial overload and ischemia became
less pronounced and peripheral edema disappeared. Three months of a
regular intake of potentiated antibodies made it possible to reduce
the daily dose of MILRINONE to 10 mg.
[0250] Potentiated antibodies to CORDARON.
[0251] P. Patient S., aged 50, had been suffering from stable
angina of effort with paroxysms of ciliary arrhythmia for 2 years.
From the onset of his illness the patient had been taking CORDARON
in a dose of 600 mg a day (3 tablets). After a year of the
treatment an increase in the frequency of paroxysms of ciliary
arrhythmia was registered. Paroxysms occurred every day; an
increase in the dose of CORDARON as well as the administration of
other antiarrhythmic drugs was inefficient. No physical or
emotional strain accounted for the paroxysms; the paroxysms cease
spontaneously. This condition seemed indicative of a thyroid
function disorder; the patient was examined by an endocrinologist
who established the diagnosis of thyrotoxicosis of a moderate
severity. The patient's thyroid profile looked as follows: TTH 1,29
mIU/l (the normal range is 0.45-6.2), total T4 180.3 nmol/l (the
normal range is 39-155), T3 3.2 nmol/l (the normal range is
1.2-3.1). The treatment with a C24 dilution of potentiated
antibodies to CORDARON in a dose of 1 tablet 3 times a day was
started. Within a month the euthyroid state was achieved. Now the
patient takes CORDARON in a dose of 100 mg a day (1/4 of a tablet 2
times a day), paroxysms of ciliary arrhythmia are rare (about once
a week).
EXAMPLE 32
Potentiated Antibodies to Hypocholesterolemic Drugs
[0252] Potentiated antibodies to PROBUCOL.
[0253] A. Patient K., aged 62, with the diagnosis of coronary
sclerosis, angina of effort, and hypercholesterolemia had been
taking PROBUCOL for 2 months along with antianginal drugs (in a
dose of 500 mg 2 times a day at mealtime). The patient complained
of dyspepsia, meteorism in the first place, the onset of which
dated back to one month after he had started taking the
preparation. The administration of a C30 dilution of potentiated
antibodies to PROBUCOL in a dose of 1 tablet a day controlled the
patient's intestinal disorders. The daily dose of PROBUCOL was
reduced by 50%.
[0254] Potentiated antibodies to NICOTINIC ACID.
[0255] B. Patient L., aged 58, had been taking NICOTINIC ACID in a
dose of 4.0 g a day for atherosclerosis of peripheral vessels
(especially pronounced in the lower extremities). The patient
complains of hot flashes and redness of the face. The intake of a
C12 dilution of potentiated antibodies to nicotinic acid in a dose
of 1 tablet 3 times a day improved the patient's tolerance of the
preparation and made it possible to reduce its dose to 1.0 g a
day.
[0256] Potentiated antibodies to PRAVASTATIN.
[0257] C. Patient F., aged 57, suffered from ischemic heart disease
and primary hypercholesterolemia. He had been taking PRAVASTATIN
for 3 months in a dose of 20 mg at bedtime along with NITROGLYCEROL
(up to 5-6 tablets a day for angina attacks). In the course of the
last 10-15 days he noticed the development of muscular weakness.
The biochemical analysis of the patient's blood revealed
transaminase levels elevated to the upper bound (ALT 50 IU/l, AST
45 IU/l). The administration of a C200 dilution of potentiated
antibodies to PRAVASTATIN in a dose of 1 tablet once a day resulted
in the improvement of the patient's condition of health, his blood
transaminase level lowered (ALT 26 IU/l, AST 21 IU/l). Angina
attacks became less frequent and the patient's intake of
nitroglycerol tablets reduced to 1-2 tablets a day.
[0258] Potentiated antibodies to ETOFIBRATE.
[0259] D. Patient P., aged 55, with an established diagnosis of
ischemic heart disease and hypercholestrolemia had been taking
ETOFIBRATE (in a dose of 500 mg once a day) following his
physician's advice. The patient stated that after a month of the
treatment with this preparation he began to suffer from abdominal
pain and meteorism. The intake of a C30 dilution of potentiated
antibodies to ETOFIBRATE in a dose of 1 tablet a day resulted in
the normalization of the patient's condition. The dose of
ETOFIBRATE was reduced by 50%. The patient's lipid metabolism
indices remained within normal limits.
[0260] Potentiated antibodies to ORLISTATE.
[0261] E. Patient O., aged 59, suffered from diabetes mellitus,
Type 2, and obesity (height 160 cm, body weight 100 kg) and had
been taking 120 mg of ORLISTATE (the inhibitor of gastric lipases)
3 times a day at meals. Within several months of the treatment
combined with low-calorie diet the patient' body weight decreased
by 7 kg; however, the patient complained of poor feeling, which was
manifested by meteorism and imperative rectal tenesmus. The
prescription of a C200 dilution of potentiated polyclonal
antibodies to ORLISTATE in a dose of 1 tablet a day improved the
patient's tolerance of the preparation, decreased her blood sugar
level, and made it possible to reduce the dose of insulin.
EXAMPLE 33
Potentiated Antibodies to Antitumor Drugs
[0262] Potentiated antibodies to DOXORUBICIN
(8S-cis)-10-[(3-amino-2,3,6-d-
idesoxy-.alpha.-L-lyxohexo-pyranozyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihy-
droxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphtacenedione).
[0263] A. Patient P., aged 61, had been receiving a course of
chemotherapy with DOXORUBICIN
(8S-cis)-10-[(3-amino-2,3,6-didesoxy-.alpha.-L-lyxohexop-
yranozyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-me-
thoxy-5,12-naphtacenedione) for lung cancer but had to stop taking
the medication because of nausea and vomiting. The prescription was
to combine the administration of the cytostatic drug with the oral
intake of a C6 solution of potentiated monoclonal antibodies to
DOXORUBICIN. As a result. the nausea subsided, which made it
possible to continue chemotherapy. Later on, DOXORUBICIN was
discontinued and the patient was put on potentiated antibodies
alone. The patient is feeling well and X-ray findings show the
arrest of tumor growth.
[0264] Potentiated antibodies to CISPLATIN
(cis-diaminodichloriplatinum).
[0265] B. Patient D., aged 57, complained of cramps in her lower
extremities during the process of chemotherapy with CISPLATIN for
ovarian cancer. A C12 dilution of potentiated monoclonal antibodies
to cis-diaminodichlorplatinum in a dose of 2 ml intramuscularly
once a day was prescribed. This drug made it possible not only to
control cramps and improve the patient's tolerance of cisplatin but
also to reduce the dose of the latter by 50%.
[0266] Potentiated antibodies to METHOTREXATE
(N-[4-[[(2,4-diamino-6-pteri-
dinyl)methyl]methylamino]benzoyl]-L-glutamic acid).
[0267] C. Patient P., aged 9, was admitted to hospital for acute
lymphoblastic leucosis. In the course of chemotherapy with
METHOTREXATE the patient started complaining of severe headaches
and nausea. The treatment with a D12 dilution of a potentiated
antiserum to METHOTREXATE in a dose of 1 tablet 2 times a day was
begun. Two days later, with continued chemotherapy, the patient
reported that his headaches disappeared and nausea subsided. He
kept taking the potentiated preparation. Two months later the
patient's condition was satisfactory and METHOTREXATE was
discontinued. Four months later, against the background of
continued monotherapy with antibodies, the patient's lymphogram was
close to normal.
[0268] Potentiated antibodies to THALIDOMIDE.
[0269] D. Patient U., aged 42, suffered from multiple myeloma. Two
bone marrow transplantations resulted in short remissions. The
third transplantation did not lead to a remission; the blood MIG
(myeloma immunoglobulin, a protein marker of tumor cells) level was
rising. The treatment with THALIDOMIDE made it possible to achieve
stable remission and the depression of the blood MIG level; however
the patient started complaining of weakness, drowsiness
constipation, and numbness sensation in his extremities. It was
suggested to use the intranasal administration of a C30 dilution of
potentiated antibodies to THALIDOMIDE in a dose of 1 ml 3 times a
day as additional treatment. After a week of treatment with
antibodies the patient started feeling better, no signs of the
progressive course of his myeloma were observed, and the blood MIG
level kept falling dramatically.
[0270] Potentiated antibodies to VERAPAMIL.
[0271] E. Patient Sh., aged 29, with an established diagnosis of
small-cell carcinoma of his left lung was going through a course of
chemotherapy with cisplatin and methotrexate. The patient was also
taking VERAPAMIL (a calcium channel blocker) in order to enhance
the tumor cell sensitivity to the treatment. After a month of the
treatment there appeared symptoms of cancer progression. Added to
the treatment protocol was the intake of a C200 dilution of
potentiated antibodies to VERAPAMIL in a dose of 1 tablet a day.
The patient started feeling better and his X-ray image showed the
arrest of tumor progression.
[0272] POTENTIATED ANTIBODIES to TOPOISOMERASE II
[0273] F. Patient T., aged 40, with an established diagnosis of
lung carcinoma underwent two courses of treatment with CISPLATIN
and ETOPOSIDE, after which clinical and X-ray findings revealed the
tumor's primary resistance to antitumor drugs. The third course of
the treatment with cytostatic drugs was combined with the
administration of a C30 dilution of potentiated antibodies to
TOPOISOMERASE II in a dose of 1 sublingual tablet once a day. The
patient started feeling better and X-ray patterns revealed the
arrest of tumor progression.
[0274] Potentiated antibodies to PROSPIDINE.
[0275] G. Patient R. aged 37 was undergoing hospital treatment with
PROSPIDINE (300 mg in the form of intramuscular injections 3 times
a week) as monochemotherapy for T lymphoma of the skin. A decrease
in the area of skin lesions (by 30%) along with improved laboratory
test data allowed the treatment to be regarded as efficient;
however, there was no further progress in the patient's condition.
The treatment was supplemented with a C200 dilution of potentiated
antibodies to PROSPIDINE in a dose of 1 tablet a day. The area of
skin lesions reduced by another 40%.
[0276] Potentiated antibodies to hormone antagonists
[0277] TAMOXIFEN
((Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylet-
hanamine).
[0278] H. Patient I., aged 47, was taking a course of chemotherapy
with TAMOXIFEN
((Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanami-
ne) for breast cancer; she complained of dizziness and nausea. The
intranasal administration of 0.5 ml of a C30 aqueous solution of
potentiated monoclonal antibodies to TAMOXIFEN 3 times a day was
prescribed. The patient's nausea subsided to a bearable level.
[0279] Potentiated antibodies to FLUTAMIDE
(2-methyl-N[4-nitro-3-(trifluor- methyl)phenyl]propanamide).
[0280] I. Patient U., aged 41, complained of fatigue and the loss
of libido and potency. The administration (in the form of
intranasal drops at bedtime) of 0.5 ml of a C12 solution of a
potentiated antiserum to FLUTAMIDE
(2-methyl-N[4-nitro-3-(trifluormethyl)phenyl]propanamide). After 10
days of the treatment the patient stated the improvement of his
ability to work and sexual activity. It was recommended to continue
the course of treatment.
EXAMPLE 34
Potentiated Antibodies to Regulators of the Blood Coagulation
Process
[0281] Potentiated antibodies to HEPARIN (mucopolysaccharide of a
polysulfuric acid ester).
[0282] A. Patient M., aged 59, complained of superficial pains in
her lower extremities. The diagnosis of trombophlebitis was
established; aqueous compresses with a D6 solution of a potentiated
antiserum to heparin at bedtime were recommended. After 5
procedures the pain and local redness subsided.
[0283] Potentiated antibodies to TICLOPIDINE
(5-[2-chlorophenyl)methyl]-4,- 5,6,7-tetrahydrothieno
3,2-c]pyridine).
[0284] B. Patient K., aged 63, complained of moderate heartaches.
The diagnosis of ischemic heart disease was made. The oral intake
(at bedtime) of 20 ml of a C30 potentiated solution of polyclonal
antibodies to TICLOPIDINE
(5-[2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno 3,2-c]pyridine)
C30 in a dose of 1 tablet 3 times a day was prescribed. After 3
months of the treatment no worsening of the disease was observed.
The conclusion was drawn about the efficiency of the potentiated
preparation for the prevention of ischemic heart disease.
EXAMPLE 35
Potentiated Antibodies to Hormonal Agents
[0285] Potentiated antibodies to INSULIN.
[0286] A. Patient R., aged 45, with an established diagnosis of
diabetes mellitus Type1 complained of ulcer of the skin integument
of his lower extremities. Local rubbing with a C30 dilution of a
30% alcoholic solution of an antiserum to insulin was included into
the scheme of combined therapy. Epithelization of skin integument
lesions was achieved.
[0287] B. Patient D., aged 52, with an established diagnosis of
diabetes mellitus Type 2 had an excessive body weight. His fasting
blood glucose level was 10 mmol/l. The glucose level correction
could not be achieved by diet and synthetic antihyperglycemic
agents. Within 3 months the daily dose of insulin increased from 5
to 25 units. The treatment with a C200 dilution of potentiated
monoclonal antiidiotypic antibodies to insulin in a dose of 1
tablet a day was started. Two weeks later the patient's sensitivity
to insulin increased; the dose of insulin was reduced to 5 units,
the fasting blood glucose level reached 5 mmol/l. After 2 months of
the treatment insulin was discontinued and the patient was switched
to therapy with antibodies alone.
[0288] C. Patient I., aged 48, suffered from a severe form of
diabetes mellitus with a high degree of insulin resistance (the
patient needed up to 128 units a day). The treatment with a C30
dilution of a potentiated antiserum to the insulin-like growth
factor in a dose of 1 tablet 3 times a day resulted in a marked
improvement of the patient's condition. His blood glucose level
dropped to 16 mmol/l. The daily dose of insulin was reduced by
50%.
[0289] Potentiated antibodies to ESTRADIOL.
[0290] D. Patient B., aged 34, was admitted to the neurology
department of a clinical hospital with complaints of rapid
uncontrollable movements in her right extremities. These symptoms
developed after a common cold. The patient gave no history of
rheumatic fever. At the time of admission the patient was pregnant
for the second time (the 21.sup.st-22.sup.nd week); she suffered
from early gestosis; there had been no complications in the course
of her first pregnancy. Before deciding to have another baby the
patient had been taking oral contraceptives. The patient was
slightly euphoric. The memory and intellect were unimpaired. Her
arterial blood pressure was 120/80 mm Hg. Hyperkinesias of her
right extremities, predominantly in her arm and hand were found.
Gynecological examination did not reveal any indication for the
termination of pregnancy. The treatment with a C200 dilution of a
potentiated form of antibodies to ESTRADIOL in a dose of 1 tablet a
day was started; a week later the symptoms of hyperkinesia
disappeared. The patient had an uncomplicated delivery at term; her
baby was in good health.
[0291] Potentiated antibodies to GLUCAGON.
[0292] Patient T., aged 64, complained of bradycardia and arterial
hypotension upon admission; she had been taking ATENOLOL. The oral
administration of a C12 dilution of potentiated polyclonal
antibodies to GLUCAGON in a dose of 1 tablet 3 times a day was
prescribed. Within 24 hours the normalization of the cardiac rhythm
and arterial pressure was achieved.
[0293] Potentiated antibodies to TRIIODOTHYRONINE (LIOTHYRONINE)
(O-(4-hydroxy-3-c-iodophenyl)-3,5-diiodo-L-thyrosine).
[0294] E. Patient D., aged 36, complained of tachycardia and
heartaches. The examination revealed no organic disorders. The oral
intake of a C12 dilution of potentiated polyclonal antibodies to
TRIIODOTHYRONINE
(O-(4-hydroxy-3-c-iodophenyl)-3,5-diiodo-L-thyrosine) in a dose of
1 tablet 3 times a day was prescribed. After 5 days of the
treatment the normalization of cardiac rhythm and the disappearance
of pain were achieved.
[0295] Potentiated antibodies to CALCITONIN.
[0296] F. Patient I., aged 58, complained of pain in her tubular
bones and soft tissues of her extremities. The examination
confirmed the diagnosis of osteoporosis. The intranasal
administration of 0.5 ml a C24 dilution of a potentiated
monospecific antiserum to CALCITONIN twice a day was prescribed
within the framework of combined therapy. Three days later the
patient started feeling better and reported the lessening of
pain.
[0297] Potentiated antibodies to the SOMATOTROPIC HORMONE.
[0298] G. Patient Ch., aged 56, had been taking a course of
treatment for obesity. Because of the oral administration of a C15
dilution of potentiated monoclonal antibodies to the somatotropic
hormone in a dose of 1 tablet 3 times a day together with a diet
the patient had lost 4 kilograms within 10 days; the dieting became
easier.
[0299] Potentiated antibodies to STEROID HORMONES.
[0300] Potentiated antibodies to HYDROCORTISONE
(11.beta.)-11,17,21-trihyd- roxypregn-4-ene-3,20-dione).
[0301] I. Patient Ts., aged 29, a welder by profession complained
of sharp pain in his eyes. Twice doses of eye drops containing a
C12 aqueous solution of a potentiated antiserum to HYDROCORTISONE
(11.beta.)-11,17,21-trihydroxypregn-4-ene-3,20-dione) made it
possible to eliminate painful sensations within 24 hours.
[0302] Potentiated antibodies to DEXAMETHASONE
(11.beta.,16.alpha.)-9-fluo-
ro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione).
[0303] J. Patient D., aged 39, complained of itching in his
nasopharynx. After intranasal administration of 1 ml of a C12
dilution of a potentiated solution of monoclonal antibodies to
DEXAMETHASONE
(11.beta.,16.alpha.)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-die-
ne-3,20-dione) itching disappeared.
[0304] Potentiated antibodies to TESTOSTERONE
((17.beta.)-17-hydroxyandros- t-4-en-3-one).
[0305] K. Patient A., aged 41, complained of the lowering of
potency. The examination revealed a moderate degree of obesity and
no organic lesions of the central nervous system. A course of
treatment with a C6 dilution of potentiated monoclonal antibodies
to TESTOSTERONE to be taken by mouth in a dose of 1 tablet 3 times
a day was proposed. At his next visit to the physician four weeks
later the patient stated that his sexual performance improved and
sexual activity enhanced. The patient had lost 5 kg; he tolerated
well his food regimen under the conditions of the preparation
intake. It was recommended to continue the course of treatment.
EXAMPLE 36
Potentiated Antibodies to Nervous System Mediators
[0306] Potentiated antibodies to ACETYLCHOLINE
(2-(acetyloxy)-N,N,N-trimet- hylethaneaminium).
[0307] A. Patient Yu., aged 58, complained of constipation. The
intranasal administration of 0.5 ml of a C50 dilution of a
potentiated solution of antibodies to ACETYLCHOLINE
(2-(acetyloxy)-N,N,N-trimethylethaneaminium) 4 times a day was
recommended. The stool was back to normal 24 hours after the intake
of the preparation.
[0308] Potentiated antibodies to NORADERNALINE.
[0309] B. Patient D., aged 71, complained of dizziness and
bradycardia. The examination revealed hypotension (100/65 mm Hg).
The oral intake of 10 ml of an antiserum to noradrenaline in a
potency of C14, 3 times a day was prescribed. At his next visit to
the physician 6 days later the patient reported feeling better and
not suffering from dizziness anymore; his blood pressure was 110/75
mm Hg. It was recommended to continue the course of treatment.
[0310] Potentiated antibodies to DOPAMINE.
[0311] C. Patient L., aged 69, complained of tremor and gait
disorders. The patient had had a long-time history of treatment
with neuroleptics for schizophrenia. The treatment was supplemented
with a C15 dilution of potentiated polyclonal antibodies to
DOPAMINE (oral intake, 1 tablet 3 times a day). Within 4 days the
tremor disappeared and no neuroleptic manifestations were
observed.
[0312] Potentiated antibodies to SEROTONIN
(5-hydroxytriptamine).
[0313] D. Patient G., aged 41, complained of the worsening of mood
and apathy. The intake of a C1000 dilution of a potentiated
solution of monoclonal antibodies to (serotonin) in the form of
drops in a dose of 1 ml twice a day was proposed. Seven days later
the patient reported the improvement of mood and the enhanced
motivation to labor. It was recommended to continue the course of
treatment.
[0314] Potentiated antibodies to ASPARTIC ACID (L-aspartic
acid).
[0315] E. Patient N., aged 75, complained of tremor of extremities.
The examination revealed no organic lesions of the nervous system.
The oral intake of a C200 dilution of a potentiated solution of
antibodies to aspartic acid in a dose of 1 tablet 3 times a day was
recommended. A new examination two days later showed the absence of
tremor.
[0316] Potentiated antibodies to GLUTAMIC ACID (L-glutamic
acid).
[0317] F. Patient M., aged 29, complained of cramps in the lower
extremities during sleep. The administration of potentiated
polyclonal antibodies to L-glutamic acid in a dose of 1 tablet by
mouth at bedtime resulted in a decrease in the frequency and
intensity of convulsions.
[0318] Potentiated antibodies to GLYCINE.
[0319] G. Patient P., aged 58, complained of restlessness and
sleeping disorders. The oral intake of a C1000 dilution of
potentiated antibodies to GLYCINE in a dose of 1 tablet at bedtime
was recommended; within two days the patient's sleep became
normal.
EXAMPLE 37
Potentiated Antibodies to Mediators of Inflammation and Allergy
[0320] Potentiated antibodies to PROSTAGLANDINS.
[0321] Potentiated antibodies to MISOPROSTOL (methyl ester of
(11.alpha.,13E)-(+-)-11,16-dihydroxy-methyl-9-oxoprost-13-en-1-ic
acid).
[0322] A. Patient K., aged 41, complained of pain in the epigastic
area after meals. The oral intake of a C50 dilution of a
potentiated solution of polyclonal antibodies to MISOPROSTOL
(methyl ester of
(11.alpha.,13E)-(+-)-11,16-dihydroxy-methyl-9-oxoprost-13-en-1-ic
acid) in a dose of 1 tablet before meals was recommended. At his
new visit to the physician seven days later the patient reported
the elimination of pain.
[0323] Potentiated antibodies to KININS.
[0324] B. Potentiated antibodies to BRADYKININ.
[0325] Patient N., aged 15, complained of dry cough. The
administration of potentiated monoclonal antibodies to bradykinin
in the form of nasal drops in a dose of 0.5 ml 3 times a day
resulted in the disappearance of cough within 2 days.
[0326] Potentiated antibodies to HISTAMINE
(1H-imidazole-4-ethanamine).
[0327] C. Patient Ts., aged 27, complained of severe itching of
insect bites. Within the framework of combined therapy compresses
with a C30 solution of potentiated antibodies to histamine were
applied to the sites of lesions. The next day the redness subsided
and the itching disappeared.
EXAMPLE 38
Potentiated Antibodies to Vitamins, Substances with Vitamin-like
Action, and Bioflavonoids
[0328] A. Patient A., aged 51, had been taking rather large doses
of ascorbic acid (5-6 g daily) with health-improvement purposes
following his friends' advice. He was admitted to hospital with an
attack of renal colic. The pain was controlled with spasmolytic
drugs and alkaline solutions. Laboratory blood tests showed high
glucose content (9 mmol/l, the normal range being from 3.3 to 5.5
mmol/l). The patient had never consulted endocrinologist and had no
family history of diabetes; therefore, the toxic effect of high
doses of ascorbic acid upon the pancreas was suggested as the cause
of the patient's elevated blood sugar content. The treatment with
potentiated antibodies to ascorbic acid in a dose of 1 tablet 3
times a day was started. Within two weeks the fasting blood glucose
content dropped to 6 mmol/l.
[0329] Potentiated antibodies to THIAMINE
(3-[(4-amino-2-methyl-5-pyrimidi-
nyl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride).
[0330] B. Patient V., aged 57, complained of pain in her left
thigh. The examination confirmed the diagnosis of neuralgia. A C200
dilution of a potentiated solution of monoclonal antibodies to
THIAMINE
(3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methylth-
iazolium chloride) in a dose of 1 tablet twice a day was
recommended. After 6 days of the treatment the lessening of the
pain intensity was achieved. A conclusion about the efficiency of
such therapy was drawn.
[0331] Potentiated antibodies to NICOTINIC ACID
(3-pyridinecarboxylic acid).
[0332] C. Patient R., aged 48, complained of hot flashes and
tachycardia after the intake of nicotinic acid she had been
receiving for atherosclerosis. The oral intake of a C30 dilution of
a potentiated solution of monoclonal antibodies to
3-pyridinecarboxylic acid in a dose of 1 tablet twice a day was
recommended. The patient noticed the subsidence of her tachycardia,
which allowed the antihypercholesterolemic therapy to be
continued.
[0333] Potentiated antibodies to TROXERUTIN
(2-[3,4-(bis(2-hydroxyethoxy)p-
henyl]-3-[[6-O-(6-desoxy-.alpha.-L-mannosopyranozyl)-.beta.-D-glucopyranoz-
yl]oxy]-5-hydroxy-7-(2-hydroxyethoxy)-4H-1-benzopyranone-4).
[0334] D. Patient U., aged 42, complained of pain after she had
bruised her thigh. The examination revealed a large hematoma.
Compresses with a C6 dilution of an aqueous solution of a
potentiated antiserum to TROXERUTIN were recommended. A new
examination two days later showed the shrinking of the hematoma;
the patient felt no pain.
[0335] Potentiated antibodies to DIHYDROERGOCRISTINE.
[0336] E. Patient K., aged 29, had been taking 1 lozenge of
ANAVENOL (the preparation composed of an .alpha.-adrenolytic agent
DIHYDROERGOCRISTINE, ESCULINE, and RUTOZIDE) 3 times a day for
varicose veins in her legs developed during pregnancy and the
postpartum period. The edema and heavy feeling in the legs were
lessening but the patient started complaining of headaches and
dizziness. Anavenol was discontinued. The treatment with a C30
dilution of potentiated antibodies to dihydroergocristine in a dose
of 1 tablet twice a day was begun. The patient's condition of
health kept improving, headaches and dizziness disappeared. Two
months later a marked regression of varicosity was registered.
[0337] Potentiated antibodies to DETRALEX bioflavonoid (contains a
combination of diosmine and hesperedin).
[0338] F. Patient V., aged 42, an operation nurse, had been
suffering from varicose veins in her legs for 5 years. Following
her doctor's recommendations, she started taking DETRALEX (1 tablet
twice a day). She complained of dyspepsia not associated with diet
faults. The treatment with a C30 dilution of potentiated antibodies
to each component alternately (every other day) in a dose of 1
tablet daily was initiated. The patient started feeling much better
after one week of the intake of the antibodies. Six weeks later no
symptoms of varicose veins were seen.
[0339] Potentiated antibodies to VITAMIN A.
(trans-9,13-dimethyl-7-(1,1,5--
trimethylcyclohexen-5-yl-6)-nonatetraen-7,9,11,13-ol).
[0340] G. Patient K., aged 26, complained of headache, running nose
and artralgia. In order to raise the patient's immunity, the oral
intake of a C200 dilution of a potentiated antiserum to VITAMIN A
(trans-9,13-dimethyl-7-(1,1,5-trimethylcyclohexen-5-yl-6)-nonatetraen-7,9-
,11,13-ol) in a dose of 1 tablet a day was prescribed. At his next
visit three days later the patient reported feeling well.
[0341] Potentiated antibodies to VITAMIN D (ERGOCALCIFEROL)
(5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol).
[0342] H. Patient N., aged 55, complained of pain in his hands not
associated with physical strain and cramps in his lower
extremities. The recommendation was: the intake of a C200 dilution
of potentiated solution of an antiserum to VITAMIN D
(ERGOCALCIFEROL) (5Z,7E,22E)-9,10-secoergost-
a-5,7,10(19),22-tetraen-3-ol) in a dose of 1 tablet 2 times a day
in combination with preparations of calcium. After three weeks of
the therapy the lessening of pain and the disappearance of
convulsive reactions were observed. It was recommended to continue
the course of treatment.
[0343] Potentiated antibodies to VITAMIN E
(3,4-dihydro-2,5,7,8,-tetrameth-
yl-2-(4,8,12,-trimethyltridecyl)-2H-1-benzopyranol acetate).
[0344] I. Patient A., aged 43, complained of fatigability and
muscle weakness. After a weeklong course of treatment with a C30
dilution of potentiated monoclonal antibodies to VITAMIN E
(3,4-dihydro-2,5,7,8,-tetr-
amethyl-2-(4,8,12,-trimethyltridecyl)-2H-1-benzopyranol acetate) in
a dose of 1 tablet 3 times a day the patient stated an increase in
his ability to work and the improvement of mood.
EXAMPLE 39
Potentiated Antibodies to Immunomodulators and Cytokines
[0345] Potentiated antibodies to INTERFERON.
[0346] A. Patient P., aged 34, complained of rhinitis and pain in
his nasopharynx. The diagnosis of acute respiratory viral infection
was established. A double administration of intranasal drops of a
potentiated C12 aqueous solution of monoclonal antibodies to
.gamma. interferon resulted in the normalization of the patient's
condition of health within two days. A conclusion was made that the
antibodies featured the antiviral effect.
[0347] Potentiated antibodies to interleukins.
[0348] Potentiated antibodies to ALDESLEUKIN (INTERLEUKIN 2).
[0349] B. Patient M., aged 42, had been running course of treatment
for the exacerbation of chronic bronchitis. The oral intake of a
C30 dilution of potentiated monoclonal antibodies to INTERLEUKIN 2
in a dose of 1 tablet 3 times a day resulted in the normalization
of the body temperature three days after the beginning of the
treatment with the homeopathic preparation. The recommendation was
to take the preparation in a dose of 1 tablet once a day for three
months. Catamnesis: no exacerbations of chronic bronchitis occurred
during 8 months of medical observation. A conclusion was made that
the antibodies possessed an immunity-boosting effect.
[0350] Potentiated antibodies to COLONY-STIMULATING FACTORS.
[0351] C. Patient L., aged 23, complained of dizziness. He had a
long (20 days) history of the intake of baralgin containing a
pyrazolone derivative with a hemopoiesis-suppressing effect. The
oral intake of a C200 dilution of potentiated polyclonal antibodies
to FILGRASTIM (COLONY-STIMULATING FACTOR) in a dose of 1 tablet 3
times a day was recommended; this made it possible to achieve
normal counts of neutrophiles and erythrocytes within 6 days after
the beginning of treatment. Conclusion: the antibodies possessed a
hemopoietic effect.
[0352] Potentiated antibodies to LEVAMIZOL.
((S)-2,3,5,6-tetrahydro-5-phen- ylimidazo[2,1-b]thiazole).
[0353] D. Patient K., aged 41, was hospitalized with an established
diagnosis of maxillary sinusitis. The administration of a C12
dilution of potentiated monoclonal antibodies to LEVAMIZOL
((S)-2,3,5,6-tetrahydro-5-- phenylimidazo[2,1-b]thiazole) in the
form of nasal drops in a dose of 0.5 ml twice a day made it
possible to control headache and to return the body temperature to
the normal level within three days. It was the immunostimulating
effect of potentiated antibodies that accounted for such
results.
[0354] E. Patient P., aged 53, suffered from the exacerbation of
her hypertensive disease; the blood pressure reached 180/100 mm Hg.
As she used to take DIBAZOL as part of her antihypertension
treatment, there was made a suggestion to start treatment with a
C30 dilution of potentiated polyclonal antibodies to DIBAZOL in a
dose of 1 tablet twice a day. Within three days her blood pressure
dropped to 150/80 mm Hg. The treatment with antibodies was
continued. Despite the fact that there was an epidemic of flu in
the city, to which all the members of the patient's family
succumbed, the patient never developed any symptoms of viral
respiratory infection. A conclusion was drawn about the hypotensive
and immunostimulating effects of the antibodies.
[0355] Potentiated antibodies to immunodepressant drugs.
[0356] F. Patient D., aged 27, complained of redness and itching of
her hands after a contact with a synthetic detergent. Her condition
was diagnosed as allergic dermatitis. The oral intake of a C200
dilution of a homeopathic solution of monoclonal antibodies to
CYCLOSPORIN in a dose of 1 tablet twice a day lessened the severity
of the allergic reaction within 24 hours.
[0357] G. Patient A., aged 28, had been staying at hospital for
basic antirheumatic therapy-resistant rheumatoid arthritis. The
patient had been treated with CYCLOSPORIN A (CsA) (2.5 mg/kg per
diem) for 4 months with good therapeutic effect. A routine blood
test showed an elevated creatinine level; the patient's blood
pressure was raising in the course of the last week (160/90 mm Hg).
The danger of the exacerbation of arthritis and the inefficiency of
other medications precluded cancellation of treatment with CsA. The
dose of CsA was reduced to 1.5 mg/kg per diem and a C200 dilution
of potentiated antibodies to CsA was prescribed in a dose of 1
tablet twice a day. After a week of the treatment the creatinine
content went back to normal, the blood pressure dropped to 120/75
mm Hg. The stable antirheumatic effect of CsA persisted along with
the patient's good tolerance of it. Later CsA was discontinued. The
intake of potentiated antibodies was continued in a dose of 1
tablet every day. Catamnesis 6 months later: rheumatoid arthritis
in the phase of remission.
[0358] H. Patient L., aged 47, complained of lumbar pain. After the
diagnosis of lumbosacral radiculitis had been established, a
recommendation was made: the oral intake of a C12 dilution of
polyclonal antibodies to CHONDROITIN SULFATE in a dose of 1 tablet
3 times a day along with conventional anti-inflammatory drugs.
After two days of the treatment the pain syndrome subsided.
Monotherapy with antibodies made it possible to begin to control
the manifestations of radiculopathy within 7 days.
[0359] I. Patient O., aged 40, had been participating in the
elimination of the consequences of the Chernobyl catastrophe; he
suffered from radiation cataract of both eyes. The patient used to
take AZAPENTACENE (2 drops into both eyes 5 times a day) to good
effect; however he complained to the attending oculist of an
itching and burning sensation in his eyelids. The suggestion was to
discontinue the administration of the preparation temporarily and
to use a D12 dilution of antibodies to AZAPENTACENE in a dose of 1
tablet twice a day. When the irritation of the patient's eyelids
had subsided, the treatment with potentiated antibodies was
successfully continued.
EXAMPLE 40
Potentiated Antibodies to Antibiotics and Antiparasite Drugs
[0360] Potentiated antibodies to CIPROFLOXACIN
(1-cyclopropyl-6-fluoro-1,4-
-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid).
[0361] A. Patient Ts., aged 26, complained of cough and pain in his
nasopharynx. Physical examination showed a rise in the body
temperature to 37.1.degree. C. After two days of the intake of a
solution of potentiated antibodies to CIPROFLOXACIN
(1-cyclopropyl-6-fluoro-1,4-dihyd-
ro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid) in a dose of
10 drops 3 times a day the patient's condition normalized and the
body temperature dropped to 36.7.degree. C.
[0362] Potentiated antibodies to METRONIDAZOLE
(2-methyl-5-nitro-1H-imidaz- ole-1-ethanol).
[0363] B. Patient A., aged 32, complained of nausea after
metronidazol intake. The additional administration a of C12
dilution of potentiated monoclonal antibodies to
2-methyl-5-nitro-1H-imidazole-1-ethanol in a dose of 1 tablet 3
times a day made it possible to eliminate nausea and continue the
treatment.
[0364] C. Potentiated antibodies to CEFEPIM
([[7-[[(2-amino-4-thiazolyl)(m-
etoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-e-
n-3-yl]methyl]-1-methylpyrrolidinium hydroxide).
[0365] Patient E., aged 36, complained of pain in his knee joints
and tonsillitis. The diagnosis of rheumatoid arthritis was
established earlier; however, concomitant duodenal ulcer precluded
the administration of anti-inflammatory drugs. The recommendation
was to take drops of a solution (a D24 dilution) of an antiserum to
the antibiotic CEFEPIM
([[7-[[(2-amino-4-thiazolyl)(metoxyimino)acetyl]amino]-2-carboxy-8-oxo-5--
thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl
]-1-methylpyrrolidinium hydroxide) 3 times a day. Five days later
the inflammatory reaction subsided and tonsillitis disappeared.
[0366] D. Patient Zh., aged 33, was directed to the proctology unit
of a clinical hospital with an established diagnosis of perianal
abscess. Within the framework of therapy the patient was receiving
AMOXYCLAV (a combination of semisynthetic penicillin amoxycillin
and clavulonic acid, an inhibitor of .beta.-lactamases), 1 tablet 3
times a day. The patient used to take various antibiotics on his
own initiative and without system, including
phenoxymethylpenicillin. Along with the amelioration of his general
condition (the lowering of the body temperature, the lessening of
pain, and the reduction of the white blood count), the patient
started complaining of nausea. Following his doctor's advice, the
patient began to take AMOXYCLAV at meals; however, nausea
persisted. A 7-days' course of the treatment with a C6 dilution of
potentiated antibodies to 6-aminopenicillanic acid (common for all
penicillins) in a dose of 1 tablet 3 times a day was carried out.
The tolerance of the preparation improved; the patient presented no
complaints, no indications for surgical treatment were seen; as the
blood count and the body temperature were back to normal, the
patient was discharged from hospital under local polyclinic
observation. Recommendations for the regimen and further treatment
were given.
[0367] E. Patient V., aged 34, suffered from severe bilateral
polysegmentary pneumonia with a II-III degree of respiratory
failure, chronic alcoholism, chronic hepatitis, secondary
immunodeficiency. The patient started receiving MAXINIM
(cephalosporin of the IV generation) in a dose of 1.0 gram
intramuscularly every 12 hours. At the 3.sup.rd day of the
treatment the patient's condition ameliorated, dyspnea and cough
subsided, and the body temperature went down. However, the paint
started complaining of nausea, his functional liver tests showed
elevated values of ALT and AST. The treatment protocol was
completed with a C50 dilution of potentiated antibodies to MAXINIM
in a dose of 1 tablet 3 times a day. The patient's condition kept
improving, the nausea disappeared, and the ALT and AST values
dropped to the upper bound of normal.
[0368] F. Patient K., aged 46, was taking RULIDE for acute
prostatitis in a dose of 150 mg twice a day. After three days of
the treatment the symptoms of prostatitis subsided but the patient
started complaining of dizziness and distorted smell and taste of
food. The treatment with a C30 dilution of potentiated antibodies
to RULIDE in a dose of 1 tablet 3 times a day was started and
within three days the taste and odor perception was back to normal
and dizziness disappeared.
[0369] G. Patient G., aged 25, suffered from the exacerbation of
chronic adnexitis after criminal abortion, polynarcomania, and
secondary immunodeficiency. She was treated with CIPROBAY (125 mg 2
times a day). After 6 days of the treatment the patient felt
better; however, she started having fainting spells and hot
flashes. A C200 dilution of potentiated antibodies to CIPROBAY in a
dose of 1 tablet twice a day was prescribed. Within the days the
patient's complaints disappeared, her condition became
satisfactory.
[0370] H. Patient Sh., aged 44, had been treated with CIPROFLOXACIN
for the exacerbation of chronic suppurative obstructive bronchitis.
The choice of the drug had been based on the results provided by
the antibioticogram; the repeated use if this medication had been
giving clinical success. However, in this case no positive
bronchological dynamics was achieved after 2 weeks of treatment.
The antibiotic was discontinued and the treatment with a C6
dilution of potentiated monoclonal antibodies to CIPROFLOXACIN in a
dose of 1 tablet twice a day began. Within ten days all symptoms of
bronchial obstruction disappeared, no suppurative mucus was seen
during bronchoscopy. A conclusion was drawn on the antibacterial
and anti-inflammatory effects of potentiated antibodies.
[0371] I. Patient I., aged 42, was staying in a phthisiologic
hospital with an established diagnosis of infiltrative tuberculosis
of the upper lobe of the right lung in the phase of disintegration
and dissemination, with bacterioexcretion. After three months of
the treatment with isoniazid, rifampicin, and streptomycin positive
clinical and X-ray dynamics was achieved. However, the subsequent
two months of the treatment with the antibacterial drugs did not
bring any significant improvement of the patient's condition:
infiltration and a cavern in the upper lobe of the right lung
persisted and showed no tendency for a further reduction; the
release of bacteria persisted as well. The in vitro resistance to
antibiotics was not found at the initial stage of examinations or
five months later. The treatment with a C200 dilution of
potentiated antibodies to ISONIAZID, RIFAMPICIN, and STREPTOMYCIN
in a dose of 1 tablet of each preparation daily made it possible to
achieve positive X-ray dynamics within two months; the release of
bacteria stopped.
[0372] J. Patient Ch., aged 36, was staying at the infectious
hospital for amebic dysentery. After four days of the
administration of ORNIDAZOLE (1.0 g per diem) the patient started
complaining of somnolence and dizziness. The additional treatment
with a C12 dilution of potentiated antibodies to ORNIDAZOLE in a
dose of 1 tablet twice a day resulted in the elimination of the
undesirable effects within subsequent four days.
EXAMPLE 41
Potentiated Antibodies to Chelating Agents
[0373] A. Patient D., aged 44, was undergoing a course of treatment
with DOXORUBICIN (75 mg administrated intravenously once in 3
weeks) at the inpatient unit of an oncological dispensary for III
degree breast cancer. For the prevention of myocardiopathy the
patient was receiving CARDIOXANE intravenously 30 minutes before
the injection of the cytostatic drug. The patient tolerated
DOXORUBICIN well enough with a background treatment with
CARDIOXANE; however, her hemoglobin level dropped to 70 g/l. It was
suggested to include the administration of a C30 dilution of
potentiated antibodies to CARDIOXANE in a dose of 1 tablet twice a
day in the treatment protocol. Within subsequent three months the
remission of the main disease was achieved and maintained; no signs
of cardiac failure were observed and the hemoglobin level was
95-100 g/l.
EXAMPLE 42
Potentiated Antibodies to Anti-gout Drugs
[0374] A. Patient Kh., aged 49, with the diagnosis of hypertensive
disease and chronic gout had been taking 1.5 g of PROBENECIDE daily
for the prevention of gout exacerbation caused by a diuretic
(hypothiazide) he was receiving for his hypertension. The patient
complained of nausea, weakness and painful sensation in his gums.
The treatment with a C12 dilution of potentiated antibodies to
PROBENECIDE in a dose of 1 tablet twice a day was started and three
days later the patient started feeling better. The treatment with
hypothiazide and PROBENECIDE was continued; the PROBENECIDE dose
was reduced by 50% with no negative effect on the therapeutic
action.
[0375] B. Patient V., aged 51, had been taking (on his physician's
advice) IMODIUM (LOPERAMIDE) for chronic diarrhea caused not by
infection (presumably by heavy metal salts). The patient stated
that the overall effect of the drug was positive but complained of
dizziness. The treatment with a C50 dilution of potentiated
antibodies to the piperidine group of IMODIUM in a dose of 1 tablet
twice a day was started and after five days of the therapy with
antibodies the unpleasant sensations ceased (with a persisting
therapeutic effect of the drug).
EXAMPLE 43
Potentiated Antibodies to Autologous Antigens
[0376] Potentiated antibodies to DNA antigens.
[0377] Patient P., aged 24, with clinical diagnosis of systemic
lupus erythematosus accompanied by kidney affection (nephrotic type
glomerulonephritis) and heart injury (myocarditis), subacute
course, III degree of activity had been taking prednisolone (50 mg
daily) and curantyl (200 mg daily). Because of the lessening of the
effect of prednisolone she was began to receive potentiated
polyclonal antibodies to native DNA isolated from lymphocytes of
the patient's peripheral blood. Antibodies were obtained by
immunization of a rabbit with subsequent purification of the
antiserum and its potentiation based on homeopathic technology. The
intake of a C1000 dilution of potentiated antibodies to
autoantigens of DNA in a dose of 1 tablet twice a day resulted in a
marked inhibition of the activity of the autoimmune process within
two weeks. The laboratory findings were as follows: ESR decreased
from 50 to 16 mm/h, the titer of the antinuclear factor lowered.
Catamnesis: 6 months of the intake of potentiated antibodies gave
clinical and laboratory remission.
EXAMPLE 44
Potentiated Antibodies to Rhesus (Rh) Factor
[0378] Patient S., aged 28, Rh.sup.31 (her husband was Rh.sup.+)
was admitted to hospital with the diagnosis of a 8-weeks'
pregnancy. This was her fourth pregnancy. She had a history of
normal first pregnancy ending with normal delivery, the second
pregnancy was interrupted by medical abortion at the term of 10
weeks, and the third pregnancy ended with antenatal death of the
fetus because of the Rh conflict at the term of 38 weeks. In order
to prevent the Rh conflict and to maintain the current pregnancy
she started to take a C200 dilution of polyclonal potentiated
antibodies to Rh factor beginning with the 8.sup.th week in a dose
of 1 tablet twice a week. Catamnesis: the therapy favored
uncomplicated pregnancy, which ended with labor at term. The baby
(Rh.sup.+) was healthy without symptoms of hemolytic disease.
EXAMPLE 45
Potentiated Antibodies to Substances Causing Intoxication and/or
Dependence
[0379] Potentiated antibodies to opiates.
[0380] A. Patient S., aged 28, had an almost uninterrupted 5-year
history of intravenous self-injections of crude homemade acetylated
opium (sultyga). He was admitted to a narcological unit 24 hours
after the last injection. The patient was irritated and gloomy and
complained of intense pains in his extremities, chills, and
insomnia. The oral intake of 10 drops of a C200 dilution of a
potentiated aqueous solution of natural antibodies to morphine
hydrochloride every 15-30 minutes was prescribed. The antibodies
had been isolated by affinity chromatography from the serum of a
patient with chronic morphine dependency. The therapy resulted in a
quick disappearance of vegetative disorders and the lessening of
the intensity of the myalgia. Six hours after the beginning of the
therapy the patient went to sleep. Two days later the withdrawal
symptoms virtually disappeared. A conclusion was drawn on the
sufficiency of monotherapy with antibodies to morphine in the case
of the opiate withdrawal syndrome.
[0381] B. Patient K., aged 21, was admitted to a narcology unit
with typical manifestations of the opiate withdrawal syndrome.
Questioning revealed that she had been abusing crude homemade
extract of poppy seed straw (koknar) in the form of intravenous
self-injections in the course of two years. A combined therapy with
a C1000 dilution of potentiated monoclonal antibodies to morphine
in a dose of 1 tablet once in 2 hours and a C200 dilution of
potentiated antibodies to codeine in a dose of 1 tablet in the
morning and 1 at bedtime was prescribed. Within 48 hours all
manifestations of the withdrawal syndrome were completely
arrested.
[0382] C. Patient I., aged 42, was emergently admitted to a
narcology unit with the diagnosis of codeine overdosage. The
patient was somnolent and had periodic bouts of nausea. The
examination revealed depressed reflexes, bradycardia, and moderate
hypotension. The patient was put on a slow intravenous infusion of
200 ml of an isotonic solution containing polyclonal potentiated
antibodies to opiates of the phenotrene group mixed in the
following proportions: 1 ml of a C200 dilution of antibodies to
morphine; 1 ml of a C1000 dilution to codeine; 1 ml of a C50
dilution to thebaine; 1 ml of a C30 dilution to pseudomorphine; 1
ml of a C12 dilution of antibodies to neopine. Within two hours
after the beginning of the treatment the symptoms of intoxication
completely disappeared.
[0383] D. Patient D., aged 16, had been inhaling heroin at least
three times a week in the course of the last 1.5 months. On his
parents' accord he was hospitalized in a restricted admission unit
for 24 days. Two days after admission he became irritable,
developed sleeping disorders, and complained of attraction to the
drug when talking to his physician. The prescription was: a C1000
dilution of potentiated polyclonal antibodies to heroin in a dose
of 1 tablet 6 times a day. Three weeks later the patient reported
even mood and satisfactory sleep and appetite. During individual
talks with a psychologist he denied having attraction to the drug.
It was recommended to keep taking antibodies to heroin in a dose of
1 tablet a day. Two months after his discharge from hospital he
(according to his mother's information) has never been noticed
taking drugs.
[0384] E. Patient Kh., aged 24, had been injecting intravenously
some crude homemade heroin preparations for three years. He was
admitted to a narcology unit in a state of sopor. In view of the
inefficiency of potentiated antibodies to heroin during his
previous treatment, it was recommended to start the oral
administration of a mixture of aqueous solutions of monoclonal
antibodies to the following synthetic and semisynthetic opiates: a
C50 dilution of antibodies to dionine (ethylmorphine); a C1000
dilution to promedol: a C30 dilution to phentanyl. Thirty minutes
later the patient became fully conscious and oriented in time. His
reflexes were moderately depressed. He told the physicians that he
had self-injected a dose of an unknown drug at the discotheque.
[0385] Potentiated antibodies to barbiturates and other soporific
drugs.
[0386] F. Patient B., aged 32, was admitted to an intensive care
unit in the status epilepticus. According to his relatives, he had
been taking various drugs of the barbiturate group both orally and
intravenously in the course of the last years. The intravenous
infusion of the following mixture of potentiated monoclonal
antibodies to barbiturates was prescribed: a C50 dilution of
antibodies to barbamyl (amytal sodium); a C200 dilution to nembutal
(ethaminal sodium); a C1000 dilution to fanodorm (cyclobarbital) in
a dose of 1 ml each. Within 15 minutes after the beginning of the
therapy the status epilepticus was controlled, the patient lapsed
into a stunned condition. During further observation at the
hospital the patient was irritated and suffered from insomnia and
dysphoria from time to time. He tried to get hold of soporific
drugs. An interview revealed that he had also been taking drugs of
the ureide group (bromural) and noxyron besides barbiturates. In
view of this the patient was advised to take a C50 dilution of
potentiated monoclonal antibodies to bromural in combination with a
C200 dilution of potentiated polyclonal antibodies to noxyron 1
tablet alternately every two hours. The patient's condition
seriously improved: there was no dysphoria, he became less torpid,
and his sleep was back to normal. He stopped searching for
soporific drugs and was discharged in a satisfactory condition.
[0387] Potentiated antibodies to cannabinoids.
[0388] G. Patient S., aged 24, was admitted to a psychiatric unit
with pronounced depressive disorders. He had had a long history of
hashish use (up to 5-8 joints a day). As the treatment with
antidepressants proved inefficient, the oral intake of 10 ml of an
aqueous solution containing the following mixture of potentiated
polyclonal antibodies to cannabinoids: a C50 dilution of antibodies
to canabidiol; a C30 dilution to cannabinol; a C200 dilution to
(-)-trans-.DELTA..sup.9-tetrahydrocanna- binol. After 10 days of
the treatment the patient's mood became even and his sleep was back
to normal. Two weeks after the beginning of the treatment with
antibodies the patient was discharged in a satisfactory
condition.
[0389] H. Patient D., aged 14, had been using drugs for 6 months.
She used to chew the so-called bang (hashish tar). She was willing
to be treated and his district narcologist prescribed potentiated
monoclonal antibodies to cannabinoids in a dose of 1 tablet every
morning according to the following scheme: a C50 dilution of
potentiated monoclonal antibodies to
.DELTA..sup.8-tetrahydrocannabinol during the first two weeks of
the month and potentiated monoclonal antibodies to
.DELTA..sup.9-tetrahydroca- nnabinolic acid during the last two
weeks. Six months of medical observation showed that the patient
had given up drug abuse. The, patient is socially adapted and
continues her studies.
[0390] Potentiated antibodies to cocaine and its metabolites.
[0391] I. Patient S., aged 28, had been using crack (a mixture of
cocaine with baking soda) for 1.5 years. He was admitted to a
therapeutic unit with the diagnosis of cachexy caused by chronic
hepatitis of an unknown origin. Two weeks of health-improving
therapy and hepatotropic treatment did not produce any significant
effect. In order to control asthenic symptoms the treatment was
supplemented with tablets of a C50 dilution of monoclonal
potentiated antibodies to cocaine (in a dose of 1 tablet twice a
day). After three weeks of the treatment the preparation was
substituted by tablets containing polyclonal antibodies to cocaine
metabolites: a C50 dilution of antibodies to benzoylecgonine and a
C200 dilution of antibodies to ecgonine. The treatment resulted in
the normalization of the patient's mood and sleep; he gained 18 kg
of weight. Two months after the beginning of the therapy the
patient was discharged in a satisfactory condition.
[0392] J. Patient O., aged 17, was brought to the narcological
restricted admission unit by her parents. In the course of the last
two months she had been self-injecting cocaine solutions
intravenously. An interview with a psychologist revealed signs of a
psychic dependence on this drug. The prescription was: a C50
dilution of polyclonal antibodies to a cocaine metabolite,
norcocaine, in a dose of 1 tablet 3 times a day during the first 10
days of hospital stay. The same pattern was applied to her second
10 days of hospital stay (a C200 dilution of polyclonal antibodies
to methylecgonine) and to the third 10-days' period (a C1000
dilution of polyclonal antibodies to hydroxycocaine) in the third
decade of her hospital stay. The treatment with homeopathic doses
of antibodies to cocaine metabolites resulted in a considerable
improvement of the patient's condition of health: her mood became
even and her sleep was back to normal. A test before discharge one
month later revealed no signs of psychic dependence. Catamnesis
four months later: the patient is socially adapted and has not been
noticed using drugs.
[0393] Potentiated antibodies to benzodiazepines.
[0394] K. Patient S. aged 38, had a 20-year long history of the
abuse of tranquilizers and psychotropic drugs of the benzodiazepine
group. Against the background of the drug abuse the patient
developed a psychoorganic syndrome with predominant astheno-apathic
symptoms and the patient was granted the 2.sup.nd degree of
disability. The scheme of nootropic treatment prescribed by the
district physician involved a long-term intake of polyclonal
potentiated antibodies to a number of benzodiazepines, namely, a
C50 dilution of antibodies to chlozepid; a C50 dilution to
diazepam; a C200 dilution to oxazepam; a C200 dilution to
nitrazepam; a C1000 dilution to lorazepam. As a result a C1000
dilution of polyclonal potentiated antibodies to clonazepam proved
to be the best choice for the patient. He had been taking them
every day in a dose of 1 tablet twice a day for 14 months, which
resulted in the improvement of his intellectual capacities and
memory. Now his behavior is well ordered; the patient is capable of
taking care of himself; his mother reports that he hasn't been
using any sedatives during this period.
[0395] Potentiated antibodies to phenylalkylamines and other
stimulants.
[0396] L. Patient C., aged 26, was admitted to a psychiatry
department with the diagnosis of psychosis caused by ephedron
abuse. Among the symptoms anxiety, alertness, alarming
expectations, and paranoid attitude prevailed. The intravenous
administration of a C50 dilution of potentiated monoclonal
antibodies to ephedron in a dose of 1 ml twice within the first
hour of treatment was prescribed. After 1.5 hours of the therapy
psychotic disorders disappeared. The patient's attitude to his
delusional episode is critical.
[0397] M. Patient Kh., aged 41, engaged at diplomatic service was
admitted to a intensive care unit because of a long period (about
18 hours) of somnolence. According to his wife's information, the
patient used to indulge alone in an intravenous administration of
some stimulants but definitely not cocaine. The prescription was: a
slow intravenous infusion of physiological saline solution
containing 1 ml of a C50 dilution of potentiated antibodies to
amphetamine and 1 ml a C30 dilution of polyclonal potentiated
antibodies to methamphetamine. Within fifteen minutes the lethargic
symptoms were arrested. The patient was fully conscious and well
oriented. He told the physician that he had administered a single
dose of amphetamine intravenously.
[0398] N. Patient T., aged 17, administered himself ephedrine
intravenously three times in the course of the last month for the
first time in his life. On his own initiative he went to seek for
narcologist's advice, as he was afraid of becoming an addict. The
prescription was: the intake of a combined preparation containing
polyclonal antibodies to ephedrine and polyclonal antibodies to
norephedrine in a potentiated form (dilutions C50 and C200,
respectively) in a dose of 1 tablet twice a day. For half a year
the patient paid regular visits to his physician twice a month and
reported no episodes of ephedrine use during this period.
[0399] O. Patient L., aged 25, sought for narcologist's advice on
his own initiative. After 1.5 years of imprisonment he had become
addicted to chifir (an extra strong tea brew) and used it at least
1-2 times a day. A C50 dilution of potentiated polyclonal
antibodies to caffeine (1,3,7-trimethylxanthine) in a dose of 1
tablet twice a day. During his subsequent visits the patient stated
that he had been drinking chifir very rarely (not more often than
once a week) but could not give it up altogether.
[0400] Potentiated antibodies to hallucinogens (psychedelic
drugs).
[0401] P. Patient K., aged 28, was brought to the psychiatric
department from a hotel where he had attracted the hotel staff's
attention by his inadequate behavior: he was contemplating
something, used to freeze suddenly and stand motionless, he was
poorly oriented in the situation around him. In response to
physician's questions the patient answered that he used to take
pieces of blotting paper impregnated with LSD sublingually. A
single dose (1 ml) of a C200 dilution of a solution containing
potentiated polyclonal antibodies to lysergic acid diethylamide
(LSD) was administered. Fifteen minutes after the administration of
the preparation the psychotic disorders were arrested.
[0402] Q. Two A. brothers, aged 16 and 19, with the diagnosis of
poisoning with dried ink fungi were admitted to a psychiatric unit.
As the quantity of potentiated preparation available at that moment
at the unit was insufficient, one of the patients received
intravenously 1 ml of a C200 dilution of potentiated polyclonal
antibodies to psilocin and the other, 1 ml of a C50 dilution of
potentiated polyclonal antibodies to psilocybin. Within an hour the
condition of both patients returned to normal, their excitement and
unrestraint disappeared, and they both went to sleep. A conclusion
was drawn on high efficiency of both preparations.
[0403] R. Patient D., aged 19, was admitted to a neurology unit for
manifestations of catalepsia. In view of the fact that the patient
had been taking the drug phenycyclidine (PCP), she underwent hourly
intramuscular administrations of 1 ml of a D3 dilution of the
solution of potentiated antibodies to phenycyclidine. Within three
hours the cataleptic syndrome was completely arrested.
[0404] S. Patient A., aged 38, has the 2.sup.nd degree of
disability because of paranoid schizophrenia. For fifteen years he
had been taking high daily doses of haloperidol in combination with
parcopan or cyclodol for the prevention of narcolepsia and had
already developed physical dependence on them. The attending
physician started reducing gradually the dose of cyclodol ending up
with replacing it completely with a C30 dilution of potentiated
polyclonal antibodies to cyclodol in a dose of 1 tablet in the
morning and 1 tablet at bedtime every day. The patient keeps taking
haloperidol and doesn't have any neuroleptic symptoms; no requests
for cyclodol prescription.
[0405] Potentiated antibodies to alkaloids of tobacco.
[0406] T. Patient I., aged 29, consulted a narcologist for tobacco
smoking. Because the neuropharmacological preparations he used to
take earlier had not succeeded to rid him of the bad habit, the
physician prescribed a C200 dilution of a potentiated antiserum to
nicotine in a dose of 1 tablet 3 times a day. Catamnesis 3 months
later was as follows: in the course of the first weeks of the
therapy with antibodies the patient's craving for tobacco was
enhanced and he smoked more often. Later on, the situation changed,
his craving receded, he was able to gradually reduce the number of
smoked cigarettes and finally to give up smoking altogether.
[0407] Potentiated antibodies to alcohol.
[0408] U. Patient B., aged 35, was admitted to a narcological
hospital with pronounced symptoms of alcohol withdrawal. A C200
dilution of potentiated monoclonal antibodies to ethanol in a dose
of 1 sublingual tablet every 15 minutes was prescribed. Within two
hours of the therapy the patient's condition significantly
improved: the tremor, hyperhydrosis, and weakness disappeared, the
patient went to sleep. Twenty-four hours later he was discharged.
Conclusion: potentiated antibodies to ethanol have a therapeutic
effect in the case of the alcohol withdrawal syndrome.
EXAMPLE 46
Potentiated Antibodies to Antigens of Fetal and Primordial Tissues
and Tissue Cultures
[0409] A. Patient A. was a newborn baby 27 days old. He was born
with symptoms of perinatal encephalopathy. As immunoenzyme
diagnostic methods had revealed elevated levels of embryotropic
neurospecific antigens in mother before this pregnancy, it was
decided to administer to the baby a C200 dilution of a potentiated
polyclonal antiserum to bovine fetal brain-specific
non-species-specific protein (antigen), 14-3-2 (brain-specific
enolase), in an oral dose of 5 drops of an aqueous solution to be
administered 3 times a day. In the course of the treatment
neurological symptoms subsided gradually; the reflexes of oral and
spinal automatism restored and muscle hypertonus receded. The baby
became calmer and started active breast sucking. A conclusion was
drawn on the efficiency of potentiated antibodies to the said fetal
antigen controlling normal morphogenesis of the central nervous
system in the treatment of perinatal encephalopathy.
[0410] B. Patient D., aged 4, with an established diagnosis of
mental retardation had been receiving a C1000 dilution of
monoclonal potentiated antibodies to primordial antigen nestin, a
protein marker of neuron stem cells, in a dose of 5 drops of an
aqueous solution once a day in the morning for six months with the
purpose of enhancing the child's intellectual capacities. After six
months of the treatment a neuropsychological examination showed
that D's intellect and memory were up to the standard age level;
the child's kindergarten tutor reported that the boy comprehended
and learned the material well in class.
[0411] C. Patient I., aged 8, with an established diagnosis of
Down's syndrome had been receiving a C200 dilution of potentiated
polyclonal antibodies to .alpha.-fetoprotein to be taken in a dose
of 1 tablet a day for the first 12 months and in a dose of 1 tablet
once in 3 days for subsequent 6 months. The neuropsychological
examination by Bailey's method revealed a marked enhancement of the
patient's intellect 1.5 years later. The patient's behavior is well
ordered; he is adapted to being with other children.
[0412] D. Patient S., aged 18, suffered from myasthenia of an
unknown origin. In view of the inefficiency of conventional drugs
the treatment was supplemented by the oral intake of a C30 dilution
of potentiated polyclonal antibodies to the culture of neuronal
stem cell of the Tera-1 line enriched with the protein extract of
the embryonic tissue in a dose of 1 ml 3 times a day for 6 months.
The combined treatment resulted in an increased tolerance of
physical strain, receded bulbar symptoms, diplopia, and ptosis,
which made it possible to reduce the daily doses of corticosteroid
drugs several times.
[0413] E. Patient M., aged 42, suffered from the
astheno-neurological syndrome accompanying the remote period of
vernal encephalitis. As conventional therapy proved its
inefficiency, it was decided to prescribe the oral intake of a C200
dilution of potentiated polyclonal antibodies to embryonic
neocortex (the antiserum was obtained by immunization of rabbits
with tissues from the occipital zone of the brain cortex of 15-day
old embryos of Wistar line rats) in a dose of 1 ml twice a day, for
6 months. In the course of treatment the patient's asthenic
symptoms became less pronounced, his ability to work was restored,
though disseminated microsymptoms persisted in his neurological
status.
[0414] F. Patient K., aged 39, suffered from chronic alcoholism,
grade II. He went to seek for narcologist's advice declaring his
desire to start a sober life and asking for a new method of
treatment because those he had already tried were of little effect.
The prescription was: a regular intake of a C1000 dilution of
polyclonal potentiated antibodies to homogenized hippocampi of
embryos of Wistar line rats (hippocampi of several dozens of
syngenic fetuses were used for immunization) in a dose of 1 tablet
once a day. The remission had been lasting for 8 months, in the
course of this period of medical observation no episodes of
consuming alcoholic beverages have been registered, the patient
states the absence of craving for alcohol.
[0415] G. Patient A., aged 8, suffered from liver cirrhosis of an
unknown etiology. As the conventional therapy had no significant
effect, the oral intake of a C4 dilution of polyclonal potentiated
antibodies to homogenized liver of the human fetus was prescribed
in a dose of 1 ml 3 times a day. During four months of the therapy
a clinical improvement of the patient's condition was observed,
manifestations of general intoxication symptoms and liver failure
subsided. The patient's emotional tone rose, the paleness of skin,
the icteric hue of the scleras, and spider-like hemangiomas
disappeared; the size of the liver diminished. A conclusion was
drawn on high efficiency of this mode of treatment.
EXAMPLE 47
Potentiated Antibodies to Tissues or Tissue Cultures
[0416] A. Patient O., aged 8, suffers from a malignant course of
insulin-dependent diabetes mellitus. The intranasal administration
of a C50 dilution of potentiated polyclonal antibodies to a culture
of insular cells of the pancreata of newborn rabbits in a dose of 1
ml 3 times a day was prescribed with therapeutic purposes. After
three months of the therapy the course of illness became stable,
the blood glucose level went down, and the disposition to
ketoacidosis receded. There were no comas or hypoglycemic episodes
during the period of the treatment and the amount of insulin intake
was reduced by 50%.
[0417] B. Patient P., aged 35, suffered from insulin-dependent
diabetes mellitus (mild course). As the patient was unwilling to
take insulin, the recommendation was to start the oral intake of 1
ml of a C50 dilution of an aqueous solution of polyclonal
potentiated antiserum to insular cells of the pancreas of a newborn
calf once a day. As a result of the monotherapy with this
preparation, the patient was feeling well. Her blood glucose level
was within normal limits. The patient did not take insulin any
more.
[0418] C. Patient V., aged 56, suffered from obstructing
atherosclerosis of coronary arteries and angina decubitus. In view
the inefficiency of conventional therapy the prescription was to
take intranasally a C30 dilution of potentiated polyclonal
antibodies to the homogenized heart of a newborn rabbit in a dose
of 3 drops of an aqueous solution 5 times a day. After six months
of the therapy the intensity of pain was reduced, the patient had
pain much more seldom and only after a sufficiently strong physical
strain; his blood lipid formula became normal and the dose of
nitrate drugs was reduced approximnately by 50%.
[0419] Thus, an analysis of the examples given above shows that the
activated form of ultra-low doses of antibodies to an antigen (a
substance or a pharmaceutical agent) does not produce the
well-known immunological effect of binding the antigen and
inhibiting its activity; on the contrary, it reproduces the
antigen's activity in a modified form, which results in a partial
or complete reduction of the pathological syndrome, in the
regulation of whose mechanisms of development the said antigen is
involved. In this case such antigen-associated side effects as
toxicity, addiction, and tolerance are absent.
[0420] In addition, activated antibodies in ultra-low doses
potentiate (reinforce) the effect of an antigen (a pharmaceutical
agent) on their combined or simultaneous administration, which
makes it possible to reduce the dose of the pharmaceutical agent
and to minimize its side effects.
[0421] The administration of activated forms of ultra-low doses of
antibodies to a substance or a pharmaceutical agent favors the
reduction of the intensity of the pathological syndromes (acute or
chronic intoxication, post-intoxication disorders, dependence)
caused by this substance or pharmaceutical agent.
[0422] Experimental studies of activated forms of ultra-low doses
of antibodies make it possible to determine their therapeutic
properties even in situations where the biological activity of the
initial antigen remains unknown.
* * * * *